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CHAPTER 1: Selenium redox cycling 
1 – 1: SUMMARY 
The biological role of selenium is a subject of intense current interest, and the 
activity of selenoenzymes is now known to be dependent upon redox cycling of selenium 
within their active sites.  Exogenously supplied or metabolically generated 
organoselenium compounds, capable of propagating a selenium redox cycle, might 
therefore supplement natural cellular defenses against the oxidizing agents generated 
during biological activity.  Phenylaminoalkyl selenides and sulfides were developed in 
our laboratory as novel substrate analogs for the enzyme dopamine β-monooxygenase.  
These selenides were shown to exhibit potent, dose-dependent antihypertensive activity 
in spontaneously hypertensive rats (SHR).  Recently, phenylaminoalkyl selenides were 
found to protect plasmid DNA and Molecular beacons from oxoperoxynitrate – mediated 
damage by scavenging this powerful cellular oxidant and forming their respective 
selenoxides as the sole selenium-containing products.  Rate constants were determined 
for the reactions of the selenoxides with cellular reductants such as GSH at physiological 
pH at 25oC.  The kinetic data obtained in current and previous research was subsequently 
used in a MatLab simulation, which showed the feasibility of selenium redox cycling by 












1 – 2: INTRODUCTION 
Dopamine β-Monooxygenase and Substrates: 
The various catecholamines – dopamine, norepinephrine, and epinephrine – are 
sequentially synthesized from L-tyrosine (L-Tyr).  Dopamine β-monooxygenase (DβM, 
1.14.17.1) is a key enzyme in catecholamine metabolism, which stereoselectively 



















DβM is found in chromaffin vesicles of the adrenal medulla and the sympathetic 
nerve vesicles of the central and the peripheral nervous systems, CNS and PNS (2, 3, 4).  
The enzyme exists in both soluble and membrane-bound forms (2). DβM is an ideal 
target for varying the peripheral adrenergic activity, because inhibition of DβM lowers 
the available stores of norepinephrine, which in turn diminishes the extent of adrenergic 
stimulation (4).  Phenylaminoalkyl sulfides and selenides were synthesized in our 
laboratory and were shown to be DβM substrates.    
Experimental evidence showed that under standard in vitro conditions DβM 
efficiently catalyzes the ascorbate-dependent oxidation of phenylaminoalkyl sulfides or 
selenides to the corresponding sulfoxides or selenoxides (5, 6, 7).  Biochemical studies 
revealed that the recycling of the selenoxide product back to the selenide was 
accomplished at the expense of reduced ascorbate, which formed dehydroascorbate 
(Asc), a ‘dead end’ metabolite and therefore lead to the inactivation of the normal 
ascorbate-dependent DβM activity (5, 6).  The equivalent recycling pathway for the 
sulfoxide product was not observed due to the less easily reducible nature of the sulfoxide 



































ClPAESe (4-chloro-phenyl-2-aminoethyl selenide): R1 = Cl, R  = H 2
ClPAESeO (4-chloro-phenyl-2-aminoethyl selenoxide): R1 = Cl, R  = H 2
FPAESe (4-fluoro-phenyl-2-aminoethyl selenide): R1 = F, R  = H 2
FPAESeO (4-fluoro-phenyl-2-aminoethyl selenoxide): R1 = F, R  = H 2
PAESe (phenyl-2-aminoethyl selenide): R1 = H, R  = H 2
PAESeO (phenyl-2-aminoethyl selenoxide): R1 = H, R  = H 2
(S)-HOMePEASe [(S)-hydroxy-α-methyl-phenyl-2-aminoethyl selenide]: R1 = OH,  
R  = CH2 3
(S)-HOMePEASeO [(S)-hydroxy-α-methyl-phenyl-2-aminoethyl selenoxide]: R1 = OH, 
R  = CH2 3
MeOPAESe (4-methoxy-phenyl-2-aminoethyl selenide): R1 = MeO, R  = H 2
MeOPAESeO (4-methoxy-phenyl-2-aminoethyl selenoxide): R1 = MeO, R  = H 2





Pharmacological testing of (S)-HOMePAESe showed that this compound exhibits 
restricted CNS permeability and oral dose-dependent antihypertensive activity in 
spontaneously hypertensive rats (SHR) (7).  
Recent experimental evidence has demonstrated that phenylaminoalkyl selenides, 
in addition to their antihypertensive properties, may also play an important role as 
scavengers of oxidizing species such as hydrogen peroxide (H O2 2) and oxoperoxynitrate 
(PN) (8). 
Oxoperoxynitrate (ONOO-/ONOOH): 
- One of the most predominant cellular oxidants is oxoperoxynitrate (ONOO ) 
formed from a diffusion-controlled reaction between nitric oxide (.NO) and superoxide 
(O .-2 ) in endothelial cells, macrophages and neutrophils during pathophysiological 
conditions involving acute and chronic inflammation, and in ischemia-reperfusion (9 - 
14).   
. .- - -NO  + O2 → ONOO   d[ONOO ]/dt = k × [. .-NO] × [O ] 2
.NO is produced by all three isoforms of nitric oxide synthase [neuronal (nNOS), 
inducible (iNOS) and endothelial (eNOS)], which under depleted concentrations of L-
arginine yield O .-2  as well (15-18).  The superoxide radical is also formed through the 
activity of enzymes such as NAD(P)H oxidases, xanthine oxidase and others (19).  The 
concentration of O .- 2 is down regulated by the superoxide dismutase (SOD)-catalyzed 
reaction of O .- 2 to form H2O  and molecular oxygen.  .2 NO is the only biomolecule that can 
effectively out - compete the SOD-catalyzed dismutation of O .-2 , hence resulting in the 
formation of ONOO- at a rate of 4 - 20 × 109 -1 -1  M  s (20). 
ONOO- is a relatively stable species under alkaline conditions, but upon 
protonation to peroxynitrous acid (ONOOH) it decays to nitrate with a rate constant of 
1.3 s-1 o at pH 7.4 and 25 C (21).  Oxoperoxynitrate is proposed to react with biological 
molecules through two main pathways (22).  The first pathway involves the direct 
reaction of ONOO-/ONOOH with the biotarget molecule.  The second pathway involves 
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the formation of an activated form of ONOOH, ONOOH*, which exhibits the biological 
activity of a hydroxyl radical:   
 








In addition, ONOO- and carbon dioxide (CO2) react with a second order rate 
constant of 5800 M-1sec-1 to form the ONOO- - CO2 adduct, which can in turn form other 
reactive intermediates such as NO . . and CO2 3  radicals or the nitrosodioxycarboxylate 
anion (O -NOCO2 2 ) by isomerization (23).  The importance of the reactivity of PN 
towards CO  is enhanced by the high in vivo concentration of CO2 2 (1 to 3 mM in blood 
plasma) and bicarbonate (HCO -3 , 12 mM in intracellular fluid and 25 to 30 mM in blood 
plasma).  Reaction of ONOO- with CO2 has been shown to enhance nitration reactions 
but inhibit hydroxylation and oxidation reactions mediated by PN (23, 24).   
PN species react with a variety of biological molecules such as lipids, DNA, 
proteins/peptides, amino acids, thiols and metalloenzymes.  For instance, 
oxoperoxynitrate causes single and double electron oxidations of sulfhydryls and thiols; 
initiates lipid peroxidation, and oxidizes or nitrates amino acids such as L-phenylalanine 
(L-Phe), L-methionine (L-Met), L-tryptophan (L-Trp) and L-tyrosine (L-Tyr) (14, 25 – 
29).  PN induces DNA damage leading to multiple forms of nuclear base modifications, 
and causes double and single strand breakage in plasmid DNA (30 – 37).  The DNA 
strand breakage has been found to activate a DNA repair enzyme poly(ADP) ribose 
polymerase (PARP), which causes depletion of NAD+ pools and can eventually lead to 
cell death (38).  PN was reported to induce apoptosis in a number of cell types such as 
thymocytes, cortical cells and HL-60 leukaemia cells (39). 
  19
 
Increased formation of PN has been linked to Alzheimer’s disease, rheumatoid 
arthritis, atherosclerosis, lung injury, amyotropic lateral sclerosis and other diseases (40 -
42).   
Protection against PN: 
There are three physiological and pharmacological strategies for protecting 
various biological targets from the unwanted effects of PN-mediated reactions: 
prevention, interception and repair.   
.- .Prevention of PN formation involves lowering the concentration of O  and NO2  
radicals.  SOD-mimics, inhibitors of xanthine oxidase and NAD(P)H oxidases inhibit the 
formation of O .- (43).  NO. formation can be down-regulated by using NOS inhibitors.   2
Interception of PN and its reactive intermediates (ONOOH*) can be accomplished 
with various endogenous and exogenously supplied scavengers, which react with this 
powerful oxidant or its precursors to form harmless products.  The effectiveness of an 
intercepting agent depends on the mechanism, kinetics and thermodynamics of its 
reaction with the O2.- . and NO  radicals, and PN species.  The third strategy is the repair of 
the PN-mediated damage.   
 To determine the detoxifying capacity of a given compound for PN, it is useful to 
consider the rate constant for its reaction with PN, its achievable concentration at site of 
oxidative stress and the ability of the scavenger to regenerate its active antioxidant form.   
Scavengers of PN: 
 Kinetics, thermodynamics, mechanism of action, regeneration ability and ease of 
diffusion across various organelle membranes of endogenous and exogenous scavengers 
of PN have been widely investigated.  For instance, various heme proteins 
(oxyhemoglobin), peroxidases (myeloperoxidase, lactoperoxidase and horseradish 
peroxidase) and synthetic metalloporphyrins effectively scavenge oxoperoxynitrate by 
catalyzing its isomerization to nitrite (44 – 48).   
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 The interest in the antioxidative properties of selenium and its derivatives has 
increased over the years as a number of Se - containing proteins, amino acids and organic 
compounds were shown to be effective scavengers of PN.  Selenomethionine (SeMet) 
and L-selenocysteine (SeCys) are two major Se - containing amino acids found in the 
body; SeCys is incorporated into specific protein sites, while SeMet randomly replaces a 
few L-methionine (Met) residues in proteins (49, 50).  There are currently 22 known 
eukaryotic selenoproteins, which are organized into two distinct selenoprotein groups on 
the basis of the location and functional properties of SeCys (51).  A SeCys-containing 
enzyme, glutathione peroxidase (GPx), reacts with PN with a second order rate constant 
of 8.0 × 106 -1 -1 M s  and effectively protects against PN-mediated oxidation and nitration 
reactions (52, 53).  The activity of GPx is catalytically maintained by reduced GSH (52, 
53). 
Small Se-containing molecules such as SeMet, SeCys and ebselen (2-phenyl-1,2-
benzisoselenazol-3(2H)-one) were shown to be effective PN scavengers in vitro studies 
(27, 53, 54).  Ebselen exhibits GPx like activity, and reduces PN to nitrite with a second 
order rate constant of 2 × 106 M-1 -1s  to yield the corresponding selenoxide as the sole 
selenium containing product (54, 55).  The oxidized product, 2-phenyl-1,2-
benzisoselenezol-3(2H)-one-1-oxide, is efficiently reduced back to ebselen either via 
GSH or thioredoxin reductase (TrxR) (51).      
  Other scavengers of PN include organotellurium compounds, catecholamines, 
flavanoids, reduced GSH, zinc - thiolate centers in DNA transcription factors and other 
antioxidants (51, 56 – 59).   
Antioxidative Role of Phenylaminoalkyl Selenides and Sulfides against PN:
Previous research showed that PAESe and PAES derivatives react with PN to 
form the corresponding selenoxides or sulfoxide with second order rate constants 
comparable to those of other known Se - and S - containing antioxidants such as SeMet 
and Met (table 1 - 1) (27, 49, 60).  (S)-HOMePAESe is the most effective scavenger of  
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aUnless otherwise specified, rate constants at pH 7.0 from Woznichak et. al. (60) 
bFrom Masumoto et. al. (54) 
cRate constant at pH 7.4, from Padmaja et. al. (49) 
dRate constant at pH 7.4, from Lee et. al. (44) 
eRate constant at pH 7.4, from Pryor et. al. (27) 
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PN according to the measured rate constant reported in Table 1 - 1, which is consistent 
with a proposed bimolecular nucleophilic displacement mechanism for the reaction of PN 
and selenide (60). 
PN has been shown to cause single- and double-strand breakage of supercoiled 
plasmid pUC19 DNA (41).  Hence, we investigated the ability of phenylaminoalkyl 
selenides and sulfides developed in our laboratory to protect pUC19 plasmid DNA 
against PN - induced damage (61).  In a typical experiment, 0.5 mM PN was incubated 
with pUC19 (25 ng / μl, pH 7.4) for 3 minutes at 25oC, and the various plasmid forms 
subsequently separated using agarose gel electrophoresis and quantified by scanning (61).  
We found that (S)-HOMePAESe, PAESe and SeMet decreased PN - mediated pUC19 
DNA damage by as much as 46 % under the experimental conditions, and the selenides 
were much more effective in this regard than their corresponding sulfur analogs (61).  
Quantitative HPLC analysis of the reaction mixtures confirmed stoichiometric formation 
of corresponding phenylaminoalkyl selenoxides or sulfoxides as the sole Se- or S- 
containing products of the PN-mediated reaction with plasmid DNA (61).  This result 
correlates with the work by Roussyn et. al., who demonstrated that both SeMet and 
SeCys protect pBluescript II KS DNA from single strand breakage caused by PN more 
efficiently than Met and Cys respectively (62). 
 Further experiments were carried out to demonstrate that redox cycling by GSH 
enhances protection of pUC19 plasmid DNA against PN-induced damage by (S)-
HOMePAESe.  In the presence of 0.25 mM (S)-HOMePAESe, the amount of DNA 
damage caused by 0.25 mM PN was reduced by 31% (n = 6), as compared to the level of 
damage in the absence of any protecting agents (61).  Addition of 0.25 mM GSH to the 
(S)-HOMePAESe / plasmid DNA / PN reaction caused a statistically significant 
enhancement of protection of up to 14.5%.  An ANOVA / Dunnet test (n = 6) was used to 
confirm that the results of the protection studies were statistically significant (61).  
Neither (S)-HOMePAESeO nor GSH alone at this concentration provided any protective 
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effects against DNA damage (61).  Recycling was confirmed by the observed reduction 
of (S)-HOMePAESeO in the presence of GSH and the stoichiometric increase in the 
selenide concentration via HPLC (61).   
The current research focused on measuring the rate constants of phenylaminoalkyl 
selenoxides and sulfoxides with GSH by a spectrophotometric methodology at pH 7.0 
and 25oC.  The ability of these Se - and S - containing compounds to be catalytically 
recycled by reducing equivalents such as GSH in the presence of PN was further 
investigated using a MatLab simulation. 
Antioxidative Role of Phenylaminoalkyl Selenides in PN – Mediated Reaction with 
Molecular Beacons:  
 Molecular Beacons (MBs) are hybridization probes used for detection of specific 
nucleic acid sequences (63).  MBs are hairpin – shaped molecules with an internally 
quenched fluorophore whose fluorescence is restored when they bind to a target nucleic 
acid (63).  They are designed in such a way that the loop portion of the molecule is a 
probe sequence complementary to a target DNA molecule (63).  The stem is formed by 
annealing the complementary arm sequences on the ends of the probe sequence.  A 
fluorescent moiety is attached to the 5’ end of one arm and a quenching moiety to the 3’ 
end of the other arm.  The stem keeps the two moieties in close proximity to each other, 
causing fluorescence of the fluorophore to be quenched by energy transfer.   
Two forms of energy transfer exist in MBs: direct energy transfer and 
fluorescence resonance transfer (FRET) (64).  The collision between the fluorophore and 
the quencher distorts the energy level of the excited fluorophore, which causes quenching 
(64).  The quenching moiety dissipates this energy in the form of heat rather than light.  
In MBs the length of the loop sequence is chosen so that the probe - target hybrid is 
stable at probing temperature (63, 64).  The stem sequence should be strong enough to 
form the hairpin structure for efficient fluorescence quenching yet still weak enough to be 
dissociated when a complimentary DNA hybridizes with the loop of MB.  Upon binding 
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the target DNA sequence, which is perfectly complimentary to the loop sequence of the 
MB molecule, the conformational changes open the hairpin, the fluorophore and 
quencher are separated and fluorescence is turned “on” (64).  DABCYL 
(dimethylaminophenylazobenzoic acid) is used as the quencher at the 3’ end of the 
sequence and Cy3 is used as the fluorophore at the 5’ end of the sequence in MB used in 






































MBs have numerous applications such as real-time monitoring of PCR, spectral 
gene typing and mutation detection, real-time enzymatic cleavage assays, RNA detection 
in living cells and others (63, 64).  The goal of this study was to investigate the reaction 
between PN and MB, and demonstrate that phenylaminoalkyl selenides protect MBs from 
  25
 
PN – mediated damage.  The products of the reaction between MB and PN were analyzed 




























1 – 3: MATERIALS AND METHODS 
Materials: 
Boric acid, dibasic potassium phosphate, glacial acetic acid (CH3COOH), 
hydroxylamine hydrochloride, H O  (30 % aqueous solution), HPLC - grade CH2 2 3CN, 
HPLC – grade trifluoroacetic acid (TFA), methanol (CH OH), MnO3 2, monobasic 
potassium phosphate, sodium hydroxide (NaOH), tris(hydroxymethyl)amino methane 
(Tris base) and urea were purchased from Fisher Scientific (Atlanta, GA).  1,2 -
Bis(dimethylamino)ethane (TEMED), diethylenetriamine pentaacetic acid (DTPA), 
ethylene diamine tetraacetic acid (EDTA), glutathione (GSH) and oxidized glutathione 
(GSSG) were obtained from Sigma Chemical Co. (St Louis, MO).  Acrylamide (99.9 %), 
ammonium persulfate (APS), bis(N,N’- methylene-bis acrylamide), Nucleic acid sample 
loading buffer, Protean II xi Single - Gel (PIIxiSG) Alignment card, PIIxiSG Casting 
Chamber, PIIxiSG comb (15 well, 1.0 mm), PIIxiSG Glass Plates (20 cm), PIIxiSG 
Power Supply, PIIxiSG 20 cm Slab Cell, PIIxiSG Spacers (1.5 mm), Silver Stain Plus 
(SSP) Development Accelerator reagent, SSP Fixative Enhancer Solution, SSP Image 
Development Agent, SSP Reduction Moderator Solution and SSP Silver Staining 
Solution were purchased from Bio-Rad Laboratories (Hercules, CA, USA).  Allsphere 
Octyl (C8, 250 x 4.6 mm, 5 µm particle size) column, equipped with Alltech guard 
cartridges (7.5 x 4.6 mm, 5 µm particle size) was obtained from Alltech (Nicholasville, 
KY).  MB 6 (5'-/Cy3/GAGTCCTTCCACGATACCAGGA-CTC/3Dab/-3') was obtained 
from Integrated DNA technologies Inc. 
Synthesis of Phenylaminoalkyl Selenides and Sulfides:  
 PAESe and PAES were synthesized and characterized by Dr. James E. Colbert as 
previously described (5, 61).  ClPAESe, FPAESe, MeOPAESe, (S)-HOMePAESe were 
prepared and characterized by Dr. Michelle M. Woznichak as reported in the literature 




Synthesis of Phenylaminoalkyl Selenoxides and Sulfoxide:   
ClPAESeO, FPAESeO, MeOPAESeO, PAESeO, PAESO and (S)-
HOMePAESeO were synthesized by H O2 2 - mediated oxidation of their corresponding 
selenides.  Briefly, the hydrochloride salt of the selenide was dissolved in 5 ml of DI H2O 
and reacted with a 30 % solution of H O2 2 in a 1:1.2 mol ratio.  The reaction was 
monitored by HPLC (C8 column, UV detection at 236 nm, flow rate of 1.5 ml/min and a 
mobile phase composed of 80 to 85 % DI H O, 20 to 15 % CH2 3CN and 0.1 % TFA), once 
complete it was quenched by the addition of granular MnO2, filtered and lyophilized 
overnight. 
Synthesis of PN: 
 PN was synthesized by the autooxidation of 10 mM hydroxylamine in 0.5 M 
aqueous NaOH containing 0.1 mM DTPA, as previously described (65, 66).  Oxygen was 
bubbled into the 200 ml solution for 3 hours at 25oC.  The resulting yellow solution was 
treated with granular MnO  to remove excess H O2 2 2, filtered and concentrated by freeze 
fractionation at -20oC.  PN concentration was determined spectrophotometrically at 302 
nm (ε -1 -1302 = 1670 M s ) in 0.5 M NaOH with a Hewlett Packard Model 8453 diode array 
spectrophotometer.     
Spectrophotometric Determination of Second Order Reaction Rates between 
Phenylaminoalkyl Selenoxides / Sulfoxide and GSH: 
 The second order rate constants for the redox reaction between phenylaminoalkyl 
selenoxides and GSH were determined spectrophotometrically under pseudo-first order 
conditions using an HP8453 diode-array spectrophotometer equipped with an HP 89090 
temperature-control accessory.  Selenoxides or PAESO (40 to 50 µM) was combined 
with GSH (0.35 to 0.6 mM) in 0.1 mM potassium phosphate buffer (final pH 7.0) at 25oC 
in a quartz cuvette, and the absorbance changes monitored at 0.5 second intervals for a 
period of 30 seconds.  Due to sufficient differences in molar extinction coefficients of 
reactants and products in the wavelength range of 230 to 300 nm, concentrations of 
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selenide / selenoxide or sulfide / sulfoxide could be determined using the multi-
component module of the Biochemical Analysis UV - visible ChemStation software 
(Figure 1 - 1: Panel A and B).  The following data analysis parameters were selected: 
within spectral processing, the derivative order was set to 1, filter length at 5 and 
polynomial degree at 3.  The wavelength range used was set at 230 to 310 nm with 1 nm 
intervals and the least squares method of data analysis employed.  The pseudo first order 
rate constants obtained from the concentration versus time plots (Figure 1 - 2, Panel A) 
were used to determine to second order rate constants for the reaction (Figure 1 - 2, Panel 
B).  Table 1 - 2 lists the second order rate constants for the reaction of phenylaminoalkyl 
selenoxides and GSH at pH 7.0 and 25oC.  
 Separation of reactants and products in the selenoxide / GSH reaction mixtures 
was accomplished on a C8 column (UV detection at 236 nm, flow rate of 1.5 ml/min and 
a mobile phase composed of 80 to 85 % DI H O, 20 to 15 % CH2 3CN and 0.1 % TFA).  
Authentic samples of GSH, GSSG, selenide / selenoxide and sulfide / sulfoxide were 
used to confirm the identity of the reaction mixtures. 
MatLab Kinetic Simulation: 
A MatLab simulation was employed to investigate the effectiveness of (S)-
HOMePAESe regeneration by GSH in the presence of PN at physiological pH using the 
second order rate constants for the reactions of (S)-HOMePAESe and PN (3010 M-1s-1, 
table 1 - 1), the selenoxide and GSH (1100 M-1s-1), and GSH and PN (580 M-1s-1) (60). 
The apparent 1st order rate constant for the decomposition of PN to nitrite under these 
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Figure 1 - 1: Panel A: Absorbance spectra of (S)-HOMePAESeO (0.04 mM); (S)-
HOMePAESe (0.04 mM); GSH (0.02 mM) and GSSG (0.1 mM) in 100 mM potassium 
phosphate buffer (pH 7.0).  Panel B: Absorbance spectra of the (S)-HOMePAESeO 
(0.045 mM) and GSH (0.35 mM) reaction mixture in 100 mM potassium phosphate 
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Figure 1 - 2: Panel A: Graph used to determine the pseudo-first order rate constant for the 
reaction of (S)-HOMePAESeO and GSH.  Panel B: Graph used to determine the second 









Table 1 - 2: Second Order Rate constants for GSH-Mediated Reduction of 
Phenylaminoalkyl Selenoxides and Sulfoxide. 
Se- and S- Containing Compound kGSH (M-1 -1 s ) at pH 7.0 and 25oC 
ClPAESeO 4060 ± 20 
FPAESeO 3450 ± 20 
CH OPAESeO 2200 ± 30 3
PAESeO 1500 ± 20 
(S)-HOMePAESeO 1100 ± 30 














Simulink, a module of MatLab, in conjunction with the kinetic derivations below were 
used in the simulation: 
- - (S)-HOMePAESe + ONOO  → (S)-HOMePAESeO + NO2
--Δ[(S)-HOMePAESe] / Δt = k  × [(S)-HOMePAESe] × [ONOO ] 1
- - 2 GSH + ONOO  → GSSG + H O + NO2 2
- --Δ[ONOO ] / Δt = k2 × 2 × [GSH] × [ONOO ] 
O 2 GSH + (S)-HOMePAESeO → (S)-HOMePAESe + GSSG + H2
Δ[(S)-HOMePAESeO] / Δt = k  × [(S)-HOMePAESeO] × [GSH] 3
ONOO- + 2 H+ -  → H O + NO2 2
--Δ[ONOO ] / Δt = k4 × [ONOO-] 
Mass balance: 
-Δ[(S)-HOMePAESe] / Δt = - k1 × [(S)-HOMePAESe] × [ONOO-] + k3 × [(S)-
HOMePAESeO] × [GSH] 
-Δ[GSH] / Δt = - 2 × k2 × [GSH] × [ONOO-] - k  × [(S)-HOMePAESeO] × [GSH] 3
-Δ[(S)-HOMePAESeO] / Δt = k  × [(S)-HOMePAESe] × [ONOO ] - k1 3 × [(S)-
HOMePAESeO] × [GSH] 
--Δ[ONOO ] / Δt = - k1 × [(S)-HOMePAESe] × [ONOO- -] – k  × [ONOO ] × [GSH] - k2 4 × 
[ONOO-] 
Investigation of Reactions between MB and PN: 
 The concentration of MB6 was determined spectrophotometrically on a HP8453 
diode - array spectrophotometer using an extinction coefficient (ε260nm) of 253,683  
-1M cm-1.                                          C  G  A 
                       A            T 
           C             A 
                       C             C 
             T           C 
     T - A 
     C - G 
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    5' Cy3   Dabcyl 3' 
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Control mixtures were prepared in a polymerase chain reaction (PCR) tube by 
combining 14 μM MB6 with PN (0.25, 0.7 or 1.4 mM) in 0.2 M potassium phosphate 
buffer (pH 6.8), gently vortexing the solution and incubating at 25oC for 15 minutes.  
Note that the pH of the reaction mixtures would differ from each other, due to the 
presence of different PN concentrations (diluted with 0.5 M NaOH).  The background 
mixture consisted of MB6 in 0.2 M potassium phosphate buffer in the absence of PN. 
The reaction mixtures were subsequently analyzed on a ABI PRISM 7700 sequence 
detection system equipped with a built-in thermal cycler, a laser to induce fluorescence, 
CCD (charge-coupled device) detector, real-time sequence detection software, and 
TaqMan reagents for the fluorogenic 5' nuclease assay.  The control and background 
mixtures were melted at 95oC, and cooled to 5o oC in 1 C increments, with an equilibration 
time at each temperature of 9.5 minutes and fluorescence measurements in the last 30 
seconds at 630 nm.  Eight thermocycles were performed and the results collected 
averaged using the real-time sequence detection software.   
Protection of MB from PN – Mediated Damage by (S)-HOMePAESe: 
 Reaction mixtures were prepared by combining 14 μM MB6 with PN (1.4 mM) 
and (S)-HOMePAESe (0.7, 0.9 or 1.4 mM) in 0.5 M potassium phosphate buffer (final 
pH 7.4), gently vortexing the solution and incubating at 25o oC or 84 C for 15 minutes.  
The control mixtures consisted of 8, 10 or 14 μM MB6 incubated with 0.8, 1 or 1.4 mM 
PN, respectively, under the same conditions as the reaction mixture.  The background 
mixture consisted of 8, 10 or 14 μM MB6 in 0.5 M potassium phosphate buffer (final pH 
7.4) in the absence of PN or (S)-HOMePAESe. The reaction, control and background 
mixtures were subsequently analyzed on a Spectra Max Gemini Dual-Scanning 
Microplate Spectrofluorometer via end-point analysis and excitation wavelength of 545 
nm and emission wavelength of 570 nm.  The Spectra Max Gemini Dual-Scanning 
Microplate Spectrofluorometer is equipped with two holographic diffraction grating 
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monochromators, the dual-scanning capability, a high-powered Xenon flash lamp, 
temperature control accessory, an auto-mixer and Softmax Pro software. 
Analysis of MB and PN Reaction Mixtures by Denaturing PAGE: 
Denaturing PAGE gel Preparation and Casting: Thirty % acrylamide / 
bisacrylamide solution was prepared by dissolving 58.0 g of acrylamide and 2 g of 
bisacrylamide in 200 ml of DI H O and stored in a light-protected container at 4o2 C.  10 × 
TBE (Tris borate buffer) was prepared by dissolving 54.0 g of Tris base, 27.5 g of boric 
acid and 20.0 ml of 0.5 M EDTA in a total volume of 500 ml, the pH was adjusted to 8.0.  
Denaturing PAGE gel mixture was prepared by combining 66.7 ml of 30 % acrylamide / 
bisacrylamide solution with 10 ml of 10 × TBE and 42.04 g of urea, upon complete 
dissolution, the volume of the solution was adjusted to a total of 100.0 ml with DI water.  
The mixture was degassed with Argon for 15 to 30 minutes.  Five ml of the denaturing 
PAGE mixture was mixed with 82.5 μl of 10 % APS, 15 μl TEMED, swirled vigorously 
and poured into a 200 x 200 x 1.5 mm PIIxiSG  Slab Cell in a PIIxiSG Casting Chamber.  
The plug for the gel was allowed to set for a few minutes, in the meantime the remainder 
of the denaturing PAGE solution was combined with 317 μl APS, 30 μl TEMED and 
poured on top of the plug, PIIxiSG comb (15 well, 1.0 mm) was placed within the gel.  
The gel was allowed to set for 45 to 60 minutes.   
Preparation of MB and PN Reaction Mixtures:  MB6 (14 μM), 1.4 mM PN and 
0.9 mM (S)-HOMePAESe were combined together in 0.5 mM potassium phosphate 
buffer (final pH 7.4) at 25oC, vortexed gently and allowed to react for 30 minutes.  The 
background reaction mixture consisted of 14 μM MB6 in 0.5 M potassium phosphate 
buffer (final pH 7.4) and the control mixture contained all reagents with the +exception 
of (S)-HOMePAESe.  The mixtures were all diluted in the same manner such that the 
final amount of MB6 was 100 ng.  The background, control and reaction mixtures were 
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subsequently diluted with an equal volume of the Bio-Rad nucleic acid loading buffer 
and loaded into the respective wells in the cast denaturing PAGE gel.  The PIIxiSG 
Casting Chamber was then filled with 1 × TBE and ran at constant voltage of 200 V for 
30 to 40 minutes.   
Silver Staining Protocol for the Denaturing PAGE Gel: After gel electrophoresis, 
the gel was placed in 400 ml of a SSP Fixative Enhancer Solution for 20 minutes.  The 
SSP Fixative Enhancer solution was prepared by combining 200 ml CH3OH, 40 ml 
CH COOH, 40 ml SSP Fixative Enhancer Concentrate and 120 ml DI H3 2O.  The fixative 
enhancer solution was subsequently decanted and the gel rinsed twice with 400 ml of DI 
water with gentle agitation.  The gel was subsequently stained with a SSP staining 
solution.  The staining solution consisted of 5 ml SSP Silver Complex solution, 5 ml SSP 
Reduction Moderator solution, 5.0 ml SSP Image Development reagent and 50 ml SSP 
Development Accelerator solution.  The gel was stained for 15 to 20 minutes until the 
desired degree of staining / contrast was obtained and then transferred to a 5% acetic acid 













1 – 4: RESULTS 
Spectrophotometric Determination of Second Order Rate Constants between 
Phenylaminoalkyl Selenoxides and GSH: 
 The antioxidant activity of phenylaminoalkyl selenides is dependent on the 
efficiency with which they are reduced once oxidized by a biological oxidant such as PN. 
Hence we were interested in investigating the mechanism of action and kinetics of 
organoselenium redox cycling.  Depending on the intracellular or extra cellular location, 
GSH is a common reducing agent present in vivo in the range of 0.1 to 10 mM, hence it 
was chosen as the reducing agent in our experiments (69).  The second order rate 
constants at pH 7.0 and 25oC were measured by a spectrophotometric methodology.  The 
stoichiometry of the reactants was 2 molecules of GSH per each molecule of 
organoselenoxide or sulfoxide, as determined by Overcast JL (70).  It was important to 
keep stoichiometry in mind when selecting the appropriate concentration range of GSH to 
be used throughout the experiments.  GSH was used in excess and the initial rate of 
phenylaminoalkyl selenoxide reduction measured.  The reaction between 
organoselenoxide and GSH yielded the corresponding selenide and GSSG, respectively, 
as shown by Overcast (70). 
 In previous work in this laboratory, the second order rate constants between 
phenylaminoalkyl selenoxides / sulfoxides and GSH at pH 5.5 and 25oC were measured 
by HPLC - UV detection (60).  The phenylaminoalkyl selenoxide was present in excess 
and the initial rate of GSH oxidation quantified.  Table 1 - 3 shows that the reduction of 
phenylaminoalkyl selenoxides by GSH is a rapid process and the second order rate of the 
reaction is less sensitive to the nucleophilic / electrophilic nature of the para-substituent, 
as indicated by the low positive ρ value of 0.133 at pH 5.5 in the Hammett plot by 
Overcast JL (70).  
In order to measure the rate constant between phenylaminoalkyl selenoxides and 








Table 1 - 3: Second Order Rate Constants for GSH-Mediated Reduction of 
Phenylaminoalkyl Selenoxides and Sulfoxide at pH 5.5a and 7.0 at 25oC Compared. 
Se- and S- Containing 
Compound 
kGSH (M-1 -1 s ) at pH 5.5 
and 25oCa
kGSH (M-1 -1 s ) at pH 7.0 and 
25oC 
ClPAESeO 230 ± 21 4060 ± 20 
FPAESeO 250 ± 12 3450 ± 20 
CH OPAESeO 290 ± 28 2200 ± 30 3
PAESeO 300 ± 16 1500 ± 20 
(S)-HOMePAESeO 300 ± 28 1100 ± 30 
PAESO No Reaction No Reaction 













pH 7.0 in a quartz cuvette at 25oC.  The reaction was initiated by the addition of 0.35 to 
0.65 mM GSH under vigorous stirring and spectrophotometric measurements made in the 
230 to 310 nm range at 0.5 second intervals over the course of 30 seconds.  It should be 
noted that in each case the spectrum of the formed selenide was sufficiently different 
from the parent selenoxide, hence making the accurate estimation of the reactant / 
product concentration possible over a time course.   
Initially a 4 x 4 matrix was used to determine the concentration of 
phenylaminoalkyl selenide or selenoxide at 4 chosen optimal wavelengths, where 
maximal change in absorbance was observed for phenylaminoalkyl selenide and 
selenoxide components.  The extinction coefficients of all of the reaction components 
determined within the concentration range used (with the exception of intermediate / 
transition species) were used in the calculations.  Subsequently, a multi-component 
module of the Biochemical Analysis UV-visible ChemStation software was used in the 
calculation of the organoselenide or organoselenoxide concentration over time by 
employing spectra of the unreacted reactants / products in the appropriate concentration 
range, as the standards and utilizing the whole wavelength range of interest (230 to 310 
nm). 
Table 1 - 3 shows that the reaction of ClPAESeO and GSH has the highest second 
order rate constant at pH 7.0 and 25oC, while the reaction of (S)-HOMePAESeO and 
GSH has the lowest.  The differences between the second order rate constants at pH 7.0 
are much more pronounced than those measured at pH 5.5 as shown in table 1 - 3. 
Recycling of Phenylaminoalkyl Selenides in the Antioxidant Action against PN: 
Previous work showed that phenylaminoalkyl selenides readily react with PN to 
yield the corresponding selenoxides as the sole Se - containing products, thereby 
protecting plasmid DNA from PN – mediated base modifications and strand breakage.  
(S)-HOMePAESe (0.5 mM) reduced the amount of nicked and linear plasmid DNA by as 
much as 46 % in a typical experiment where 0.5 mM PN was incubated with 25 ng / μl of 
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DNA, and the DNA plasmid forms separated via agarose gel electrophoresis and 
quantified.  
Current work showed that 1.4 mM PN can also cause irreversible damage to a 
small biosensor oligonucleotide beacon MB6 (14 μM) at 40oC and alkaline pH as 
determined using a real-time ABI PRISM 7700 sequence detection system.  The level of 
damage was quantified in terms of fluorescence changes with time at 630 nm, when the 
PN / MB6 control and background mixtures heated to 95oC were cooled to 5o oC in 1 C 
increments.  The melting temperature of MB6’s 7-base pair stem is below 95oC, hence 
MB6 is expected to exhibit the highest fluorescence intensity at this temperature.  The 
increase in fluorescence at 630 nm is due to the complete separation of a quenched 
fluorophore (Cy3 at the 5’ end of the oligonucleotide sequence) from the quenching 
moiety (DABCYL) at the 3’ end, in the absence of a complementary DNA target 
sequence.  Lower PN concentrations of 0.25 mM and 0.7 mM did not yield maximal 
fluorescence readings below 70oC, indicating that the stem in some MB6 molecules 
remained intact.  The fluorescence intensity was not indicative of the number of MB6 
products formed upon reaction with PN, which was further investigated by denaturing 
PAGE.   
(S)-HOMePAESe at a concentration of 0.7, 0.9 or 1.0 mM protected MB6 from 
reacting with 1.4 mM PN at pH 7.4 and either 25o oC or 85 C.  For example, both 0.9 and 
1.0 mM (S)-HOMePEASe completely inhibited fluorescence emission at 570 nm at 25oC, 
indicating that the stem remained intact keeping the quencher and fluorophore together.  
Overall higher end - point fluorescence values at 570 nm were collected at 85oC versus 
25oC.  Fluorescence readings in control mixtures consisting of MB6 and PN decreased, 
with decreasing concentration of PN and MB6 (MB concentration varied from 14 μM to 
10 μM and finally to 8 μM, while PN concentration was lowered from 1.4 mM to 1.0 mM 




Table 1 - 4: End – Point Fluorescence Measurements at 25o oC and 85 C in Background, 
Control and Reaction Mixtures Consisting of MB6 and PN at pH 7.5 and either 25oC or 
85oC. 
Data Collected at 25oC 
Background Fluorescence Control FU Protection FU 
Reaction Reading (FU) Reaction Reaction 
14 μM MB6 94 14 μM MB6 837 14 μM MB6 97 
1.4 mM PN 1.4 mM PN 
1.0 mM Se 
10 μM MB6 79 10 μM MB6 648 14 μM MB6 79 
1 mM PN 1.4 mM PN 
0.9 mM Se 
8 μM MB6 72 8 μM MB6 546 14 μM MB6 169 
0.8 mM PN 1.4 mM PN 
0.7 mM Se 
Data Collected at 85oC 
Background Fluorescence Control FU Protection FU 
Reaction Reading (FU) Reaction Reaction 
14 μM MB6 109 14 μM MB6 987 14 μM MB6 126 
1.4 mM PN 1.4 mM PN 
1.0 mM Se 
10 μM MB6 97 10 μM MB6 727 14 μM MB6 119 
1 mM PN 1.4 mM PN 
0.9 mM Se 
8 μM MB6 91 8 μM MB6 630 14 μM MB6 191 
0.8 mM PN 1.4 mM PN 
0.7 mM Se 
  41
 
studies with GSH were carried out.  The separation of products in MB6 / PN reaction 
mixture by denaturing PAGE did not yield meaningful results due to problems associated 
with visualizing the oligonucleotide products via silver staining.  
Further experiments were carried out to demonstrate that selenium redox cycling 
by GSH enhances protection of plasmid DNA from PN-mediated damage.  In the 
presence of 0.25 mM (S)-HOMePAESe, the amount of DNA damage caused by 0.25 mM 
PN was reduced by 31 % (n = 6), as compared to the level of damage in the absence of 
any protecting agents.  Addition of 0.25 mM GSH to the typical reaction mixture 
containing organoselenide (0.25 mM), PN (0.25 mM) and plasmid DNA resulted in a 
statistically significant enhancement of protection of up to 14.5 % (n = 6, 
ANOVA/Dunnett test).  It should be noted that neither (S)-HOMePAESeO (0.25 mM) or 
GSH (0.25 mM) provided any protective effects against PN-induced DNA damage.  The 
occurrence of recycling was confirmed by the observed reduction of (S)-HOMePAESeO 
concentration and the stoichiometric increase in (S)-HOMePAESe concentration via 
HPLC. 
MatLab Kinetic Simulation:
The rate constants measured for the reactions between phenylaminoalkyl 
selenides and PN, phenylaminoalkyl selenoxides and GSH, PN and GSH, and finally 
protonation of PN were used to design a model to predict the extent of redox cycling in 
the antioxidant activity of organoselenides at neutral pH.  Keeping in mind that (S)-
HOMePAESe is the most efficient scavenger of PN at pH 7.0 and the facility with which 
PN oxidizes various biological targets, the recycling ability of (S)-HOMePAESe was 
investigated.   
The MatLab simulation (Simulink module) was employed to model the feasibility 
of (S)-HOMePAESe regeneration from the product selenoxide by GSH in the presence of 
PN at physiological pH and 25oC.  The model used the rate constants for the reaction of 
(S)-HOMePAESe and PN (3010 M-1 -1 -1 -1s ), (S)-HOMePAESeO and GSH (1100 M s , 
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-1 -1Table 1 - 3), GSH and PN (580 M s ) and decomposition of protonated PN species (0.5 
s-1) at pH 7.0 and 25oC (47, 60, 61).  The initial concentrations of the reacting species 
were the same as those used in the DNA-nicking experiments, but the rate of nicking of 
the plasmid DNA by PN remains unknown and hence was not taken into account in the 
simulation.  
Figure 1 - 3 shows how the concentrations of (S)-HOMePAESe, (S)-
HOMePAESeO, GSH and PN would change with time at physiological pH and 25oC.  
The degree of recycling (i.e. the fraction of selenoxide converted back to selenide before 
all PN is consumed) was approximately 25 % when equivalent concentrations (0.25 mM) 
of GSH, (S)-HOMePAESe and PN were used.  Further simulations were carried out 
using the physiological range of GSH (0.1 – 10 mM), 0.25 mM (S)-HOMePAESe and 
0.25 mM PN, and the degree of recycling ranged from 5 to 100 % (69). 
The experimental work described in this chapter shows that phenylaminoalkyl 
selenoxides readily react with reducing equivalents such as GSH to regenerate the 
corresponding selenides.  The MatLab simulation and experimental data demonstrate that 
the antioxidant activity of phenylaminoalkyl selenides against cellular oxidants, such as 
PN, is enhanced in the presence of reducing equivalents such as GSH.  Therefore, in 
addition to their potent antihypertensive activity, PAESe and its para-substituted 









































































Figure 1 - 3: Predicted changes in concentration of (S)-HOMePAESe, (S)-
HOMePAESeO, GSH and PN. 
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1 – 5: DISCUSSION 
The biological role of selenium is a subject that is attracting a great deal of current 
interest.  Selenium has been recognized as an important ‘dietary antioxidant’ and Se 
deficiency has been linked to various diseases (7).  The biochemistry and pharmacology 
of selenium and its derivatives has been linked with improvement of the following 
conditions: cancer risk reduction, asthma, atherosclerosis, Dermatitis herpetiformis, heart 
attack, HIV, infertility (males), phenylketonuria (PKU), rheumatoid arthritis, cardiac 
arrhythmia, cardiomyopathy, Kashin-Beck disease, depression, diabetes, hypothyroidism, 
liver cirrhosis, macular degeneration, Osgood Schlatter disease and retinopathy (71).  
Therefore various synthetic organoselenium compounds have been used as antioxidants, 
enzyme modulators, anti - tumor, anti - microbial and anti - hypertensive agents (71).   
There is an increasing body of information, which shows that selenium and its 
derivatives play a key role in the cellular antioxidant defense mechanism.  A well-studied 
antioxidant role of Se arises from its presence in the form of a SeCys residue in the 
glutathione peroxidase (GPx) selenoenzyme family, thioredoxin reductases (TrxR), 
thioredoxin (TRx), selenoprotein P, selenoprotein W and others (71-73).  GPx enzymes 
efficiently scavenge hydroperoxides and their catalytic activity is maintained by GSH.  In 
addition GPx was shown to effectively reduce PN with a second order rate constant of 8 * 
106 M–1 -1 s (52).  TrxR, selenoprotein P and W also play a role as antioxidants in the 
defense mechanisms that minimize the extent of oxidative stress to which the cells are 
exposed to (71). 
Reactive oxygen and nitrogen species such as H O2 2, hypochlorite, PN and others 
are formed endogenously during the normal aerobic metabolism and respiration of the 
cell as well as during pathological conditions associated with chronic infections and 
diseases.  PN is a powerful oxidant formed in vivo from nitric oxide (.NO) and superoxide 
(O .-2 ) with a rate constant of 4 - 20 × 109 M-1 -1s  (46).  It reacts with a number of 
biological targets such as lipids, DNA, sulfhydryls, proteins and can often cause 
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irreparable damage to cellular components.  The biological reactivity of PN has resulted 
in the association of this species with a number of diseases such as rheumatoid arthritis, 
Alzheimer’s disease, atherosclerosis, lung injury and many others.   
Previous research showed that PAESe and its derivatives, developed as novel anti 
- hypertensive agents in our laboratory, react with PN to form the corresponding 
selenoxides with second order rate constants comparable to those of other known Se-
containing antioxidants such as SeMet (59).  The fact that the organoselenides containing 
an electron - donating substituent such as HO- or MeO- react with PN at a faster rate than 
those containing an electron - withdrawing substituent such as Cl- or F- in the para 
position is consistent with a bimolecular nucleophilic displacement (SN2) mechanism for 
the reaction of the selenide with PN.  A similar mechanism was postulated by Pryor et. 
al. for the 2 electron oxidation of Met by PN and by Padmaja et. al. for the reaction of 
SeMet with PN (27, 74).   
More recently, we found that phenylaminoalkyl selenides protect plasmid DNA 
from PN-induced damage in a manner comparable to that of SeMet.  (S)-HOMePAESe at 
a concentration of 0.9 mM was inhibitory to the reaction of 14 μM MB6 with 1.4 mM PN 
at pH 7.4 and 25oC, which resulted in complete separation of the MB stem in the absence 
of (S)-HOMePAESe.  In addition, the extent of plasmid DNA protection was enhanced 
by the presence of GSH, which functions as a reducing agent of PN and the 
phenylaminoalkyl selenoxide species, formed from the reaction of the corresponding 
selenide and PN.  Similarly, the addition of GSH resulted in the synergistically enhanced 
protection by SeMet against the oxidizing action of PN on dihydrorhodamine (DHR, a 
commonly used fluorescent probe to study PN activity) (75).   
The efficiency of a scavenger at preventing PN-mediated reactions depends not 
only on its reactivity product but also on the ability of its reaction with the oxidant to be 
catalytically maintained.  GSH is a common reducing equivalent present in vivo in 
millimolar concentrations and in vivo production of PN is expected to be continuous 
  46
 
resulting in a steady state concentration of this oxidant and hence continuous reactivity 
towards the biological targets.  The current project studied the efficiency of redox cycling 
of phenylaminoalkyl selenides by measuring the second order rate constants of the 
reactions between phenylaminoalkyl selenoxides and GSH spectrophotometrically and 
thereafter using the measured rates in a MatLab simulation.   
Table 1 - 2 shows that the reduction of phenylaminoalkyl selenoxides by GSH is a 
rapid process and similar results have been reported with other selenoxides and thiols (76, 
77).  There was no observable reaction between the sulfoxide (PAESO) and GSH.  Table 
1 - 3 shows that the reduction of the phenylaminoalkyl selenoxides by GSH to their 
corresponding selenides is pH dependent and the para-substituent effect is less 
pronounced at pH 5.5 vs. pH 7.0 at 25oC.  As expected, the reductant : selenoxide 
stoichiometry was 2 : 1 and the reaction rate was first order with respect to selenoxide 
and GSH, respectively.   
Chen et. al. have proposed a thioselenurane intermediate for the reaction of 
methylphenyl-selenoxide with GSH and our kinetic data for GSH oxidation is consistent 
with such an analogous thioselenurane intermediate (Figure 1 - 4, Panel A).  In addition 
Figure 1 - 4, Panel B shows that our ρ value of (+ 0.9 ± 0.2), for rate constants measured 
at pH 7.0, differs markedly from the large negative ρ values reported for nucleophilic 
attack of GSH and other thiols on various electrophiles (77).  This result is consistent 
with the rate limiting breakdown of the intermediate, where attack of GSH is not 
occurring directly on the benzylic “selen-oxy” moiety.   
The kinetic data collected by our and other laboratories were then used in a 
MatLab simulation to confirm the effectiveness of the redox cycling of (S)-HOMePAESe 
in the presence of GSH and PN.  The simulation showed that the extent of recycling was 
approximately 25 % when equivalent concentrations of GSH, PN and (S)-HOMePAESe 









































































Figure 1 - 4: Panel A: Proposed mechanism of phenylaminoalkyl selenide redox cycling.  
Panel B: Hammett plot demonstrating the dependence of the second order rate constants 




fraction of (S)-HOMePAESeO converted back to its selenide form before all PN is used 
up in the reaction.  Under physiological concentrations of GSH (0.1 to 10 mM) and 0.25 
mM concentrations of (S)-HOMePAESe and PN the amount of recycling ranged from 5 
to 100 %.   
The simulation results agreed with the experimental data, where 0.25 mM PN was 
incubated with 25 ng / μl pUC19 plasmid DNA for 20 minutes at pH 8.0 and 25oC (61).  
The supercoiled, nicked and linear forms of the plasmid were subsequently separated by 
agarose gel electrophoresis and quantified by scanning (ethidium bromide was used to 
visualize the bands).  In the presence of 0.25 mM (S)-HOMePAESe, DNA damage was 
reduced by 31 % (n = 6), as compared to controls in the absence of the selenide (61).  
Reverse phase HPLC confirmed stoichiometric formation of the corresponding (S)-
HOMePAESeO (approximately 47 μM) during the PN -mediated reactions (61).  Neither 
(S)-HOMePAESeO or GSH alone at a concentration of 0.25 mM protected plasmid DNA 
from PN-induced damage.  However, addition of 0.25 mM GSH to the (S)-HOMePAESe 
/ PN / DNA reaction caused a statistically significant (ANOVA/Dunnett test [n = 6]) 
enhancement of protection of up to 14.5 % (61).  The occurrence of recycling was 
confirmed by the stoichiometric reduction in the selenoxide concentration using HPLC.  
The results are once again consistent with the theory of catalytic cycling of the selenoxide 
back to the selenide form by GSH in the DNA nicking assay. 
Conclusion: 
 The results of this study provide further evidence that, in addition to their 
antihypertensive properties, phenylaminoalkyl selenides may also play an important role 
as antioxidants against powerful oxidizing species such as PN.  The maintenance of the 
catalytic activity of phenylaminoalkyl selenides such as (S)-HOMePAESe by GSH as PN 
scavengers GSH was supported by kinetic studies, MatLab simulation, the results from 
the DNA nicking assays in the presence of (S)-HOMePAESe, GSH and PN, and the 
HPLC analysis of the corresponding reaction mixtures. 
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Isolation and Characterization of a Stimulatory Component from Tissue of Loblolly Pine 
for Multiplication of Somatic Embryos 
2 – 1: SUMMARY 
Loblolly pine (LP, Pinus taeda) is the primary commercial species in southern forests 
covering 11.7 million hectares.  Somatic embryogenesis (SE) is an effective technique to 
implement clonal tree production of high value genotypes from various breeding and 
genetic engineering programs.  SE is a multi-step process, which includes initiation of 
somatic embryo (SME) growth from parent tree tissue, maintenance and multiplication of 
early stage SMEs and the maturation/germination phase.  In this work, we isolated a 
substance from stage 2 or 3 LP female gametophyte (FG) tissue that stimulates early 
stage SME growth, and we then characterized this stimulatory substance as citric acid on 
the basis of 1H NMR and mass spectrometry.  We then demonstrated that topical 
application of citric acid to SMEs stimulates embryo colony growth at p = 0.05 for a 
combination of 3 of the 5 genotypes tested.  Moreover, we find that there is a good 
correlation between the amount of citric acid isolated from FG tissue (65 nmoles per 
stage 2-3 FG) and the amount of citric acid that stimulates colony growth (25 to 50 
nmoles) when applied topically to SMEs.  This unique approach of isolating and 
characterizing a molecule from plant tissue, and investigating its role on SE processes can 
provide valuable information about the importance of various biological molecules at 






2 – 2: INTRODUCTION 
Loblolly pine (LP, Pinus taeda): 
In the Plantae kingdom, the seed producing organisms belong to the division 
Pinophyta (1).  Gymnosperms are a group of vascular plants whose seeds are not 
enclosed by a ripened ovary (fruit) (1).  The Gymnosperms are further divided into orders 
such as Pinales (1).  In North America, the order Pinales contains commercially 
important families such as pines (Pinaceae), cypress (Cupressaceae), etc.  Forestry-
associated products are the second most valuable agricultural product in USA.  Loblolly 
pine (LP, Pinus taeda) is the primary commercial species in southern forests with 1-1.5 
billion LP seedlings planted a year (2).    Somatic embryogenesis (SE) and organogenesis 
are effective means to implement clonal tree production of high value genotypes from 
various breeding and genetic engineering programs (3 - 6).   
Reproduction in Gymnosperms: 
 In temperate climates pines have a 3-year reproduction cycle.  A mature pine tree 
develops both male and female organs; microsporangia (catkins) and megasporangia 
(conelets), respectively, in separate strobili (cones) on the same tree in late summer (1).  
Pollination occurs in spring, where the microsporangia are shed, while the small 
megasporangiate cones persist in development into mid- to late- summer, when the 
growth of the pollen tube and ovule stops and resumes the following spring (1).  
Fertilization occurs that spring and seeds mature by fall.  The quality of the seed crop and 
their germination potential depends on temperature; light intensity and length of 
photoperiod; nutrition and physiology (balance of bioregulators).  Under proper 
conditions the seed germinates and develops into a seedling, it passes through a juvenile 




Generally, the male strobili are located predominantly on the lower and side 
branches of the pine tree and consist of an axis on which microsporophylls are borne.  On 
the underside of each microsporophyll, are two microsporangia that open during spring 
and discharge vast quantities of pollen.  The pollen grain has an air sac or bladder 
attached to it on each side.  The female strobili are typically located on the upper part of 
the crown and consist of an axis upon which ovuliferous scales are arranged.  The ovules 
are encased by a nucellus and a seed coat with a distinct micropylar and chalazel ends 
(1).   
At the time of pollination, the scales of the female strobili are slightly separated 
and the pollen grain comes in contact with the nucellus tissue through the micropyle end, 
at which point the pollen tube begins to grow into the tissue (1).  During the first cell 
division of the nucellus, the number of chromosomes is reduced by half giving rise to the 
female gametophyte tissue (FG) also called the endosperm, which has a haploid number 
of chromosomes.  Almost a year after pollination, 2 to 6 archegonia are formed at the 
micropylar end of the endosperm, each containing an egg cell and large cells filled with 
cytoplasm and lipoprotein-packed vacuoles (1).  After a period of winter rest, the pollen 
tube finally reaches the FG tissue and fertilization takes place.  The resulting zygote has a 
diploid number of chromosomes, half from the sperm nucleus of the pollen tube and half 
from the ovule nucleus (1).  There are several archegonia within the FG tissue containing 
more ovules susceptible to fertilization, which could result in polyembryony (production 
of several embryos per seed).  In addition, more embryos can be produced by a process 
referred to as cleavage polyembryony, where the embryonal mass within an archegonium 
gives rise to 4 separate embryos.  In reality, only 1 or 2 of these embryos actually develop 
to maturity (1). 
Embryo Development in Gymnosperms: 
Embryo development in gymnosperms can be divided into several stages; the first 
stage is proembryogenesis, which is the time prior to the formation of the suspensor 
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system (7).  The second stage is termed early embryogenesis, which involves suspensor 
elongation and formation of the root meristem (7).  Finally, the third stage is called late 
embryogenesis, which involves the formation of the polar meristems of the root and shoot 
(7).   Scheme 2 - 1 shows a further classification system, developed by Pullman and 
Webb (1994), where LP embryogenesis was subdivided into nine distinct stages based on 
morphological characteristics of the embryo (8).   
During the proembryogenesis stage, the proembryo is nourished by the egg 
cytoplasm through the suspensor system (7).  The proembryo consists of four tiers of 
cells, the uppermost tier, two embryonal tiers and finally the suspensor tier.  The cells of 
the uppermost tier are closest to the micropyle end of the archegonium and have no cell 
walls on the upper side, which is contiguous with the egg cytoplasm.  The cells of the 
embryonal tiers divide to form a conspicuous mass of cells while the cells of the 
suspensor tier elongate (7).   
In the two later stages of the embryo development, the nourishment is provided by 
the FG, which contains various cellular metabolites (starch, proteins etc.).  During the 
second stage of embryogenesis, proliferation and elongation of the suspensor cells takes 
place, embryonal call mass continues to grow and the protoderm is established (7).  In 
these early stages of embryo development, the whole embryo-suspensor complex is an 
intertwined mass of tubular and isodiametric cells. 
During the late embryogenesis phase, cellular differentiation in the embryonal 
mass takes place such that a maturing zygotic embryo consists of a shoot apical 
meristem, embryonic cortex, epidermis, embryonic pith, procambium, root cap and root 
meristem.  Initially, a clear demarcation between the cells of the proximal apex and the 
suspensor region is established.  The cells of the proximal region to the micropyle are the 
forerunners of the root cap, while the cells of the distal region become the hypocotyl, 






























Scheme 2 - 1: LP Zygotic Embryogenesis – Stages 1 through 9.2. 
  61
 
The pith is one of the first tissues in the hypocotyl-shoot axis region to be defined, and is 
surrounded by dividing cells, which become the origin of the procambium before 
cotyledons are established (7).  The apical meristem subsequently gives rise to the 
cotyledons and to the epicotyl.  Further development of the embryo subsequently 
involves increase in size and tissue differentiation.  The primary meristems are precursors 
of the basic plant organization: epidermal tissue is derived from the protoderm; primary 
conducting tissue is formed from procambium, and fundamental tissue (parenchyma, 
sclerenchyma and collenchyma) originates from the ground meristem (1).  The cells of 
permanent tissues can again become capable of division, giving rise to secondary 
meristems: vascular cambium (bark), cork cambium and phellogen (1).   
LP Somatic Embryogenesis: 
SE is a technique of producing embryos asexually in tissue culture, where somatic 
embryos (SMEs) develop into structures resembling zygotic embryos through a 
characteristic embryogenesis process but in the absence of gamete fusion.  SE is a multi-
step process, which includes initiation of SME growth from parent tree tissue, 
maintenance and multiplication of stage 1 to 2 SMEs; the development and maturation 
phase and the germination phase (8 - 11).  Scheme 2 - 2 shows the morphological 
changes in the structure of the somatic embryo as it goes through various stages of the 
development process. 
In pines, the initiation step includes selection of an explant, such as a female 
gametophyte (FG) containing zygotic embryo(s), from a female pollinated cone (12).  In 
LP the megagametophyte (FG) containing one or more zygotic embryos is used as the 
explant, where an embryogenic mass containing at least one SME extrudes from the 
micropylar end of FG in successfully initiated tissue culture systems (11).  The plant 
growth regulators, auxin (2,4-dichlorophenoxyacetic acid [2,4-D]) and cytokinin (N6-

































The importance of concentration of plant growth hormones in explant tissues, as 
well as the nature, ratio and level of plant growth regulators (such as auxins, cytokinins, 
gibberellins, abscisic acid, ethylene, brassinosteroids and polyamines) in the initiation 
medium, has been underscored by research reported by various laboratories (13).    
The initiation phase is followed by the maintenance and multiplication step, 
which ensures that numerous early stage SMEs can be produced from the previously 
initiated culture.  Maintenance media can be liquid or semi-solid and the former 
demonstrated higher multiplication rates, ease of manipulation of SE cultures and the 
added advantage of continuous mixing of reagents that SMEs are exposed to.   
During the development and maturation phase, SMEs are induced to develop into 
late stage embryos capable of germination.  Maturation of SMEs is typically achieved on 
a semi-solid medium over 3 to 6 weeks.  Unfortunately many of the embryos do not 
develop beyond stage 9.1 and hence exhibit no or low germination (5).  The germination 
assay involves the transfer of mature embryos on a basal medium for 6 to 8 weeks under 
a 16 hour light / 8 hour dark photoperiod.  At the end of the growth period the root and 
shoot growth are quantified. 
Usefulness of SE in LP: 
 Forestry products are widely used in the paper making industry, construction, as a 
source of energy and other ways.  There are a number of ways to increase the yield of 
favorable tree genotypes including breeding programs of preferred trees, plant cutting, 
micro propagation, mass control pollination and, finally, clonal forestry, where either 
superior tree genotypes or genetically engineered trees are mass produced.  Depending on 
the intended use of the preferred tree genotype or transgenic tree, desirable tree 
characteristics that are propagated from generation to generation include disease 
resistance, increased growth rates, insect resistance, favorable lignin to cellulose ratio for 
minimizing the cost of paper making etc.  
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 The technique of SE is currently used to mass produce industrially and 
environmentally important tree families such as Eucalyptus and Populus.  Mass 
production of favorable LP genotypes by the process of SE has lagged behind that of the 
formerly mentioned families.  Factors that limit commercialization of LP SE include low 
initiation rates, low culture survival, the inability of SMEs to fully develop and 
germinate, and recalcitrance of favored genotypes over time.  Additional concerns with 
LP SE are plant tissue maintenance (resources and labor costs), time consuming field 
trials and other factors.  Improvements in the various phases of LP SE processes are 
therefore needed (14). 
Bottlenecks in SE of Loblolly Pine: 
Numerous improvements in the preparation of initiation, multiplication, 
maturation and basal culture media for LP SE and organogenesis have been made over 
the years via supplementation with metal ions, endogenous and chemically synthesized 
plant growth regulators, amino acids, vitamins, organic acids, activated charcoal, 
carbohydrates and other additives (5, 6, 11, 15-21).  The changes in composition of 
initiation, multiplication and maturation media for SE were based either on a trial and 
error methodology, or more systematically on analyses of FG and zygotic embryo tissue 
from various stages of development.  In previously published work FG and zygotic 
embryo tissue from different stages of development, obtained from several tree sources, 
was analyzed for organic acid content and key elemental composition by gas 
chromatography / mass spectrometry (GC/MS) and inductively coupled emission 
spectroscopy, respectively (5, 14).  Based on the changes in concentration of the analytes 
across stages in development, the appropriate SE growth media were supplemented with 
specific amounts/ratios of organic acids, vitamins and / or elements.  For example, 
altering the concentrations of boron, calcium, potassium, and iron in the maturation 
media resulted in an increase in LP cotyledonary embryo yields.  However, the stage to 
which SMEs matured and the germination potential of the embryos were not changed by 
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these media changes (19).  Supplementation of SE initiation media with various 
combinations of Vitamin B12 and E, α-ketoglutaric, succinic and pyruvic acids resulted 
in increases in initiation of LP SMEs (17).   
Recent studies have shown that a water extract from LP FG tissue of stage 2 or 3 
promotes growth of early stage LP SMEs in a statistically significant manner as shown in 
figure 2 - 1.  Therefore, the aim of this study was to isolate, characterize and quantify the 
stimulatory material present in LP FG tissue of stages 2 and 3.  We report herein that the 
stimulatory material in water-extracted FG tissue was isolated by a protocol involving 
HPLC fractionation as shown in scheme 2 - 3 and then characterized as citric acid on the 
basis of 1H NMR and mass spectrometry (MS).  The amount of citric acid in FG tissue of 
stage 2 or 3 was quantified via HPLC, and topical application of the appropriate citric 
acid concentration to the surface of early stage SMEs was found statistically stimulatory 
to embryo colony growth for a combination of 3 out of the 5 genotypes tested.  This 
unique approach of isolating and characterizing a molecule from plant tissue that exerts a 
desired effect on one or more stages of the SE processes can be used with plant species 
other than LP.  Investigations of this nature not only improve the effectiveness of SE 
media but also provide valuable information about the importance of various biological 


































Figure 2 - 1: The effect of FG Extract from Various Stages on the Multiplication of 




















 1.  Crush, suspend in H2O for 60 mins 
 
2.  Centrifuge 
 
3.  Filter sterilize, add 0.1 % TFA (v/v) in 
H O 2
 
4.  C18 RP Cartridge; 0.1 % TFA (v/v) in 
H O 2
 























6.  HPLC (Alltech C18) 
 












2 – 3: MATERIALS AND METHODS 
Materials: 
Abscisic acid (ABA), N-(4-aminobenzoyl)-glycine, ammonium nitrate, 6-
benzylaminopurine (BAP), biotin, boric acid, calcium nitrate tetrahydrate, cobalt chloride 
hexahydrate, copper sulfate pentahydrate, folic acid, Gelrite, glutamine, glycine, iron 
sulfate heptahydrate, kinetin, magnesium chloride hexahydrate, magnesium nitrate 
hexahydrate, magnesium sulfate heptahydrate, manganese sulfate heptahydrate, N-
morpholinoethanesulfonic acid (MES), myo-inositol, nicotinic acid, m-nitrobenzyl 
alcohol, potassium iodide, potassium hydroxide, thiamine hydrochloride and zinc sulfate 
heptahydrate were obtained from Sigma Aldrich (St Louis, MO, USA).  Citric acid, 
Corning Costar Cell culture plates, HPLC grade CH OH, CH CN, H SO3 3 2 4 and 
trifluoroacetic acid (TFA) were obtained from Fisher Scientific (Pittsburgh, PA, USA).  
Casamino acids were purchased from Beckton Dickinson (Franklin Lanes, NJ, USA).  
2,4-Dichlorophenoxyacetic acid was purchased from Chem Service (West Chester, PA, 
USA).  DL-isocitric acid was obtained from Acros Organics (Morris Plains, NJ, USA).  
Potassium dihydrogen phosphate, potassium hydrogen phosphate, potassium nitrate, 
sodium EDTA and sucrose were obtained from JT Baker (Phillipsburg, NJ, USA).  
Prevail C18 column (250 x 4.6 mm, 5 μm particle size) and Prevail guard cartridges (4 x 
3 mm) were purchased from Waters Corporation (Milford, MA, USA).  Allsphere semi-
prep C18 column (250 x 10 mm, 5 μm particle size) was obtained from Alltech 
(Deerfield, IL, USA).  C18 guard cartridges (4 x 3 mm) were purchased from 
Phenomenex (Torrance, CA, USA).  Vydac C18 column (150 x 0.3 mm, 3 μm particle 
size) was obtained from Grace Vydac (Hesparia, CA, USA).  Nexus C18 solid phase 
extraction cartridges were obtained from Varian (Palo Alto, CA, USA).  Acrodisc syringe 
filter (0.2 μm HT Tuffryn membrane, low protein binding and non-pyrogenic) was 





Loblolly pine (LP, Pinus taeda) cones were collected from open – pollinated 
mother trees, UC5-1036 (Union Camp located in a seed orchard near Belville, GA, USA) 
and S4PT6 (seed orchards located in LA and TX, USA).  The cones were received within 
24 to 48 hours after the collection period and stored at 4oC.  Cones were pried open, and 
the female gametophyte (FG) extracted from seeds cracked open with a hemostat.  FG 
was slit open, and the dominant embryo(s) removed and examined under the dissecting 
microscope in order to determine the stage of the embryo.  Twenty embryos of the same 
stage were collected in a vial, frozen under liquid nitrogen and stored at –70oC.  The 
corresponding FGs (20) were similarly stored.  The embryos were staged using the 
system of Pullman and Webb (1994).  Typically stages 2 to 3 occurred in mid-June, 
approximately 4 weeks after estimated fertilization. 
FG Tissue Extraction: 
FG frozen tissue (from stage 2 or 3) was crushed into a fine powder using a 
mortar and pestle under liquid nitrogen.  The resulting powder was extracted with 
deionized (DI) water (2 ml per 20 FGs) by stirring the suspended FG tissue at 4oC for 60 
minutes.  The mixture was subsequently centrifuged at 20,000 × g and 25oC for 5 minutes 
and the supernatant collected.  The pellet was washed with minimal DI water, centrifuged 
and the wash combined with the supernatant.  FG extract was filter-sterilized through a 
0.2 μm membrane and treated with a 0.1 % (v/v) aqueous TFA solution for 10 minutes at 
0oC.  The resulting mixture was centrifuged using a bench top Damon/IEC centrifuge at 
approximately 10,000 × g and 25oC for 5 minutes, the pellet discarded, the supernatant 
collected and lyophilized to dryness.  The resulting lyophil was dissolved in 1 ml of 0.1 
% (v/v) aqueous TFA solution, applied onto a Varian Nexus solid-phase cartridge and the 
flow-through collected.  The cartridge was eluted with 1 ml of 0.1 % (v/v) TFA and the 




HPLC Fractionation of FG Extract: 
 The first HPLC fractionation was carried out on a Waters LC Module I Plus 
HPLC equipped with Millenium chromatography manager software (Milford, MA, USA) 
and using an Allsphere ODS-2 column with a Phenomenex ODS-2 guard cartridge.  
Lyophilized FG extract was dissolved in 200 μl of DI water and one-half was 
fractionated in each of the two separate HPLC runs, the fractionation was carried out 
under linear gradient elution with CH OH (0.1 % [v/v] TFA) (A) / H3 2O (0.1 % [v/v] 
TFA) (B) mobile phases: 0 to 12 mins (3% A / 97 % B), 12 to 25 mins (3% A / 97% B to 
14% A / 86 %B), 25 to 45 mins (14% A / 86% B to 25% A / 75% B) with UV detection 
at 215 nm and a flow rate of 4.7 ml min-1.  Fractions S1 through S6 were collected and 
lyophilized to dryness, retention times are listed in Table 2 - 1. 
The next HPLC fractionation was performed on the same apparatus using a 
Prevail C18 column with a corresponding Prevail C18 guard cartridge.  Fraction S2 was 
dissolved in 200 μl of DI water and injected in two separate aliquots onto the column, 
fractionation was carried out under isocratic elution conditions with aqueous 0.1 % (v/v) 
TFA (UV detection at 215 nm and a flow rate of 0.7 ml min-1).  Fractions S2-1 through 
S2-7 were collected and lyophilized to dryness; corresponding retention times are listed 
in Table 2 - 2. 
Preparation of maintenance and multiplication media (1133 and 1250): 
Plant Tissue Culture: 
Media components and concentrations (1133 and 1250) are listed in Table 2 - 3.  
Typically the media were prepared by combining all the reagents with the exception of 
abscisic acid (ABA), glutamine and citric acid in DI water, adjusting the pH to 5.7 with 1 
N KOH and autoclaving the resulting mixture in absence (1133) or presence (1250) of 
Gelrite using the liquid cycle (highest temperature of 121oC).  ABA, glutamine and 
sometimes citric acid were filter-sterilized through a 0.2 μm membrane, added to the 




Table 2 - 1: Effect of fractionated FG extract on early-stage SME growth (HPLC 
fractionation #1). 
Fraction (treatment in 
bioassay) 
Retention time (min) Change in colony diameter 
(mm) (2 bioassays) 
S1 2 to 3.7 0.10, *2.25 
*S2 3.7 to 4.5 0.90, *2.10 
S3 4.5 to 5 0.61, *1.37 
S4 5 to 7 0.06, 0.26 
S5 12.5 to 14.5 - 0.02, 0.44 
S6 23.5 to 27 - 0.15, 0.38 
*Represents a statistically significant change in mean colony diameter (95% LSD 
intervals) of FG-extract-treated SMEs compared to the control treatment. 
 
 
Table 2 - 2: Effect of fractionated FG extract on early-stage SME growth (HPLC 
fractionation #2). 
Fraction (treatment in 
bioassay) 
Retention time (min) Change in colony diameter 
(mm) (2 bioassays) 
S2-1 3.5 to 5.5 - 0.37, 0.11 
S2-2 6.0 to 8.0 0.03, - 0.01 
S2-3 8.0 to 10.0 0.62, - 0.76 
S2-4 10.0 to 13.0 0.32, - 0.58 
S2-5 14.5 to 15.0 - 0.12, - 0.30 
*S2-6 15.5 to 17.0 1.81, *3.19 
S2-7 17.0 to 18.5 - 0.15, - 0.75 
*Represents a statistically significant change in mean colony diameter (95% LSD 





Table 2 - 3: Maintenance and Multiplication Media Components 
Media Components 1133 (mg/L) 1250 (mg/L) 
Maintenance Medium Multiplication Medium 
NH NO 603.8 603.8 4 3
KNO 909.9 909.9 3
KH PO 136.1 136.1 2 4
Ca(NO ) .4H O 236.2 236.1 3 2 2
MgSO .7H O 246.5 246.5 4 2
Mg(NO )3 2.6H O 256.5 256.5 2
MgCl2.6H O 101.7 101.7 2
KI 4.15 4.15 
H BO 15.5 15.5 3 4
MnSO .H O 10.5 10.5 4 2
ZnSO .7H O 14.4 14.4 4 2
Na MoO .2H O 0.125 0.125 2 4 2
CuSO .5H O 0.125 0.125 4 2
CoCl .6H O 0.125 0.125 2 2
FeSO .7H O 6.95 9.95 4 2
Na EDTA 9.33 9.33 2
Sucrose 30,000 30,000 
Myo-inositol 1,000 1,000 
Casamino Acids 500 500 
L-Glutamine 450 450 
Thiamine.HCl 1.0 1.0 
Pyridoxine HCl 0.5 0.5 
Nicotinic Acid 0.5 0.5 
Glycine 2.0 2.0 
MES - 250 
Biotin - 0.05 
Folic Acid - 0.5 
2,4-D 1.1 1.1 
BAP 0.45 0.45 
Kinetin 0.43 0.43 











LP SME Multiplication Assay: 
 SME of stage 1 or 2 was isolated from liquid maintenance medium 1133 and 
placed on approximately 2 ml of 1250 medium.  Lyophils from HPLC fractions were 
dissolved in 2 ml of 10 mM MES (pH 5.7), pH adjusted to 5.7 with KOH if necessary 
and filter-sterilized through a 0.2 μm membrane.  50 μl of each fraction (equivalent to 
material from half a FG) was applied to each SME previously placed on medium 1250 (4 
replicates of 10 embryos per treatment) and allowed to grow in the dark at 23-25oC for 4 
to 6 weeks.  The control experiment (treatment 0) consisted of 40 embryos with no 
extract applied to them.  At the end of the growth period the embryogenic tissue diameter 
was measured with a dissecting microscope (typically a single stage embryo is on 
average 1.0 mm in size and will grow to form an embryogenic mass 5 to 9 mm in 
diameter).  The data was evaluated by multifactor analysis of variance, significant 
differences between treatment means were determined by the Multiple Range Test at 95 
% or 90 % level of significance using Statgraphics Plus Version 4.0.  
Characterization of S2-6 via MS and 1H NMR: 
Experiment 1: Electron spray ionization liquid chromatography / mass spectrometry 
(ESI LC/MS) protocol: 
The LC-MS system was comprised of an Applied Biosystems QSTAR-XL 
quadrupole / time – of - flight tandem mass spectrometer (TOF MS MS) interfaced with 
capillary LC pumps, autosampler, and a micro switching device.  LC fractionation of S2 
was carried out on a Vydac C18 column at a flow rate of 4 μL min-1 and UV detection at 
210 nm using gradient elution with 98:2 H O:CH2 3CN (0.05 % [v/v] TFA) (A) / 20:80 
H O:CH2 3CN (0.04 % [v/v] TFA) (B) mobile phases.  The elution protocol consisted of a 
1 minute column pre-equilibration with 100% A, followed by 5 μL sample injection, a 5 
minute sample load and wash with 100% A, a 45 minute linear gradient to 100% B, and a 
5 minute hold at 100% B.  The capillary HPLC was directly connected to the QSTAR-XL 
where subsequent dispersal and desolvation of the eluent occurred.  The turbo ion spray 
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needle was held at –3500 V and the declustering and focusing potentials were held low at 
-40 V and -200 V, respectively to prevent ions from fragmenting at the source.  
Subsequently formed ions were detected using negative ion TOF MS acquisitions from 
200 to 2000 atomic mass units (AMU). 
Experiment 2: Fast Atom Bombardment (FAB) MS Analysis of fraction S2-6 and citric 
acid: 
FAB MS was carried out on the VG-70 SE two sector mass spectrometer 
equipped with an AUF axis photomultiplier detector (8 KV acceleration voltage).  Exact 
mass of fraction S2-6 was determined to be 191.0197, corresponding to molecular weight 
of citric acid within 2.5 ppm (in negative mode).  m-Nitrobenzyl alcohol (employed as 
the matrix) and N-(4-aminobenzoyl)-glycine were used as low and high molecular weight 
calibrators respectively.  
Experiment 3: 1H NMR of S2-6 and citric acid were determined on a 500 MHz Bruker 
DRX instrument.  1H NMR chemical shifts in D2O of citric acid were δ 2.96 (d, 2H), δ 
2.78 (d, 2H) and of S2-6 in D2O were δ 2.88 (d, 2H), δ 2.73 (d, 2H), respectively. 
HPLC quantitation and further analysis of S2-6: 
 The amount of citric acid present in S2-6 was quantified using 0.5 to 10 mM citric 
acid calibration curve obtained on the Prevail C18 column equipped with the Prevail C18 
guard cartridge under isocratic elution conditions with 0.1 % (v/v) aqueous TFA and UV 
detection at 215 nm.  S2-6 fraction spiked with citric acid was then further analyzed 
under three isocratic elution conditions with 99:1 H O (0.1 % [v/v] TFA):CH2 3OH (0.1% 
[v/v] TFA) (MP1), H O (0.1 % [v/v] TFA) (MP2) and H SO  (pH 1.5) (MP3). 2 2 4
Effect of Citric Acid and Other Additives on LP SME Multiplication Assay: 
Experiment 1: Dependence of SME growth on concentration of topically applied citric 
acid 
A 50 μl aliquot of 0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM or 2.0 mM citric acid in 
10 mM MES (pH 5.7), filter sterilized through a 0.2 μm membrane, was applied to each 
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stage 1-2 SME of genotype 500 on medium 1250 (4 replicates of 10 embryos per 
treatment) and allowed to grow in the dark at 23-25oC for 4 to 6 weeks.  In treatment 0 
(control) no extract was applied to the early stage SMEs.  Additional experiments showed 
that higher concentrations of citric acid (greater than 2 mM) are not stimulatory to SME 
at p = 0.05 (data not included). 
In control experiments, 50 μl of 10 mM MES buffer (pH 5.7) or 50 μl of 10 mM 
MES buffer with an appropriate amount of KOH necessary to neutralize 0.5 mM citric 
acid (pH 6.0) or 1.0 mM citric acid (pH 6.3), filter sterilized through a 0.2 μm membrane, 
was added to  individual embryos of genotype 500 on medium 1250. 
In additional control experiments 50 μl of 0.5 mM or 1.0 mM glutaric acid in 10 
mM MES (pH 5.7), filter sterilized through a 0.2 μm membrane, was applied to each 
stage 1-2 SME of genotype 500 on medium 1250. 
Experiment 2: Comparison of 3 different methods of application of citric acid on SME 
growth: 
50 μl of 0.5 mM or 1 mM citric acid in 10 mM MES buffer (pH 5.7), filter 
sterilized through a 0.2 μm membrane, was added to each stage 1-2 SME of genotype 
500 on medium 1250 (4 replicates of 10 embryos per treatment) or stage 1-2 SMEs were 
placed on medium 1250 containing 0.0125 mM or 0.025 mM citric acid (added to 1250 
medium before or after autoclaving).  The control experiment consisted of 40 embryos 
grown in the absence of citric acid. 
Experiment 3: Effect of topically applied 0.5 mM and 1 mM citric acid on SME growth 
of 3 genotypes. 
50 μl of 0.5 mM or 1.0 mM citric acid in 10 mM MES (pH 5.7), filter sterilized 
through a 0.2 μm membrane, was applied to each stage 1-2 SME of 3 different genotypes 
placed on medium 1250 (4 replicates of 10 embryos of a single genotype per treatment) 
and allowed to grow in the dark at 23-25oC for 4 to 6 weeks.  The control experiment 
(treatment 0) consisted of 40 embryos with no extract applied to them. 
  76
 
2 – 4: RESULTS 
Isolation of Stimulatory Material from Early Stage LP FG Tissue: 
Studies carried out by Pullman et. al. (2007) have shown that a water extract from 
FG tissue of stage 2 or 3 is stimulatory to growth of an early stage SME as compared to 
control experiments where no FG extract is applied to the embryos.  Therefore, a protocol 
involving HPLC with aqueous-organic gradient and isocratic elution profiles was 
developed to isolate the stimulatory component present in FG tissue.  The final procedure 
for isolating the stimulatory material from early stage FG material (trees S4PT6 and 
UC5-1036) entailed initial water extraction from crushed tissue for an hour at 4oC, 
removal of proteins by TFA precipitation, and further purification of FG extract using a 
Nexus Varian extraction cartridge.  The TFA - eluted fraction from the cartridge was 
further fractionated on a C18 column with gradient aqueous / organic elution.  Fractions 
S1 (2 to 3.7 min), S2 (3.7 to 4.5 min) and S3 (4.5 to 5 min) were found to be stimulatory 
at p = 0.05 to early stage SME growth of genotype 500 as compared to the control 
treatment, where no fractionated FG material was applied to the embryos (Figure 2 - 2 
and Table 2 - 1).  Subsequently, only fraction S2 was found to be consistently stimulatory 
at p = 0.05 to early stage SME growth, where the mean colony diameter increased by 
0.90 mm (bioassay 1) and 2.10 mm (bioassay 2) as compared to the control treatments.  
Hence one can conclude that fractions S1 and S3 likely contain molecules stimulatory to 
early stage SME growth that are more sensitive to concentration changes than the 
compounds present in fraction S2. 
ESI LC/MS analysis indicated that S2 contains several other components, which 
were further fractionated on a Prevail C18 column under isocratic elution conditions with 
an aqueous acidic mobile phase (Figure 2 - 2, inset).  The sixth fraction, S2-6 (15.5 to 17 






























Figure 2 - 2.  HPLC fractionations of stage 2 or 3 FG tissue extracts performed as 
described in the MATERIALS AND METHODS section.  See tables 2 - 1 and 2 - 2 for 




compared to the control at p = 0.05 in two separate bioassays.  The mean embryo colony 
diameter increased by 1.81 mm (bioassay 1) and 3.19 mm (bioassay 2) as compared to 
the controls where early stage SMEs grew in the absence of S2-6 (Table 2 - 2).  Fraction 
S1 was also further fractionated under identical elution conditions but none of the 
separated components were found to be consistently stimulatory at p = 0.05 to early stage 
SME growth (data not shown). 
Characterization of Stimulatory Material from Early Stage LP FG Tissue:
Fraction S2-6 was subsequently analyzed using FAB MS in negative mode.  A 
peak at 191 (m/z) was observed in the spectrum, which at an exact molecular weight of 
191.01965 matched a compound of a molecular formula (C6H7O7) within 2.4 ppm 
(Figure 2 - 3).  To conclusively characterize the structure of S2-6, the fraction was 
analyzed by 1H NMR and found to consist of citric acid.  Further HPLC analysis of S2-6 
spiked with citric acid under three different elution conditions supported the conclusion 
that the only component in this fraction was citric acid (Figure 2 - 4, panel A).  It should 
be noted that citric and isocitric acids (structural isomers) have different retention times 
under the same elution conditions as depicted in Figure 2 - 4, panel B. 
The amount of citric acid in S2-6 from different experiments was quantified using 
HPLC as described in the experimental section.  On the average, 20 FGs from stage 2 or 
3 were found to contain 1.30 μmoles of citric acid, which corresponds to 32.5 nmoles in 
half a megagametophyte.  Therefore, citric acid in the range of 25 to 50 nmoles was used 
in the treatment of a single early stage SME in the growth assay.  This is in good 
agreement with a previous report where the amount of citric and isocitric acids in FG 
tissue from various stages of development was quantified by GC/MS and found to be 
33.3 nmoles in half a FG of stage 3 (14). 
Further bioassays to identify the concentrations of citric acid that would be most 
stimulatory to early stage SME colony growth were carried out.  It was found that 
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Figure 2 - 4.  Panel A: Overlaid chromatograms of S2-6 spiked with citric acid using 3 
different mobile phases (MP1, MP2 and MP3), see MATERIALS AND METHODS 
section.  Panel B: Overlaid chromatograms of citric and isocitric acids using elution with 
MP2. 
  
concentrations of 0.5 mM (25 nmol per SME) to 1 mM (50 nmol per SME) were 
consistently stimulatory at p = 0.05 to SME multiplication of genotype 500 as compared 
to the control treatments when applied directly to the surface of the embryo (Figure 2 - 5 
and Table 2 - 4).  When the same amounts of citric acid were added to the multiplication 
medium before or after autoclaving, it was found that the stimulatory effect on SME 
growth of genotype 500 was less pronounced than when citric acid was applied topically.  
For example, promotion of SME growth of genotype 500 was statistically significant in 
all bioassays only when 0.5 mM citric acid was added topically to the embryo surface but 
not when the same amount (0.0125 mM) was added to the medium before autoclaving 
(Figure 2 - 5, panel B and Table 2 - 4).  When citric acid at concentrations of 0.0125 mM 
or 0.025 mM was added to the multiplication medium after autoclaving, it was found that 
colony growth of genotype 500 was increased compared to the control but not in a 
statistically significant manner at p = 0.05.  This observation may be explained by the 
fact that citric acid is more readily available to the growing SME when placed on the 
surface of the embryo versus within the medium, where it has a longer exposure to 
components of growth medium 1250 at a higher temperature.  Hence the amount of citric 
acid available to growing SMEs would depend on the concentration and oxidation state 
of reacting/chelating species within the multiplication medium, growth rate of SME, 
duration of bioassay, pH fluctuations and temperature.  Dalton et. al. (1983) 
demonstrated that approximately 45% of the iron present in Murashige and Skoog 
medium precipitated as iron phosphate after ferrous EDTA rapidly oxidized to ferric 
EDTA (23).  Previous investigations by van Winkle (2001) showed that Fe (III) 
precipitation as phosphate or hydroxide was reduced by addition of 10 μM citrate to the 
Norway spruce initiation medium, thus increasing its availability (24). 
Additional experiments using 2 different combinations of 3 LP genotypes were 
subsequently carried out.  Table 2 - 5 shows that 0.5 mM citric acid applied topically to 




























Figure 2 - 5.  Panel A: Effect of different citric acid concentrations on growth of early 
stage SMEs.   Panel B: Topical application of citric acid compared to direct addition of 
citric acid prior to autoclaving to medium 1250 on SME growth. 
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Table 2 - 4: Effect on SME growth of three different methods of application of various 
citric acid concentrations. 
[Citric Acid] mM Change in Colony Diameter (mm) 
(1 to 3 bioassays) 
0.0125+, Ω *0.97+, 1.13+, 0.16Ω
0.025+, Ω *1.55+, *1.74+, 0.37Ω
0.05Ψ 0.74Ψ
*0.10Ψ 2.07Ψ
*0.50Ψ 3.90Ψ, *2.11Ψ, *2.83Ψ
*1.00Ψ 2.4Ψ, *1.74Ψ, *2.34Ψ 
*2.00Ψ 3.06Ψ
+Citric acid added to medium 1250 before autoclaving (genotype 500 SMEs).  Ω Citric 
acid added to medium 1250 after autoclaving (genotype 500 SMEs).  ΨCitric acid applied 
to the surface of SMEs (genotype 500) on medium 1250.  *Represents a statistically 
significant change in mean colony diameter (95% LSD intervals) of SMEs grown in the 
presence of citric acid compared to the control treatment. 
 
 
Table 2 - 5: Topical application of optimal citric acid concentrations on early-stage SMEs 
of different genotypes. 
                                                                Change in colony diameter (mm) 
Genotypes Genotypes  
[Citric acid] (mM) 500, 351 and 60 500, 112 and 146 
*0.50 0.98 0.72 
1.00 - 0.16 - 0.02 
*Represents a statistically significant change in mean colony diameter of SMEs grown in 




effect of the same amount of citric acid was stimulatory to SME growth of genotypes 
500, 112 or 146 only at p = 0.1. 
A possible concern with above experiments was the effect of 10 mM MES buffer 
and different amounts of KOH used to maintain citric acid solutions at pH 5.7 on SME 
growth assay.  Control bioassays showed that neither MES nor additional KOH had a 
statistically significant effect at p = 0.05 on colony growth.  In addition, we found that 
topical application of a biologically inactive chemical osmoticant, glutaric acid at 0.5 mM 



































2 – 5: DISCUSSION 
In previous work, improvements in LP SE media were made using either a trial 
and error approach or a more systematic methodology, where molecules found or 
suspected to be present in nutritive FG tissue surrounding the LP zygotic embryo within 
the seed were used as supplements (5, 6, 11, 15-21).  For example, the concentrations of 
organic acids present in FG and zygotic tissues at various stages of development were 
profiled using GC/MS (14).  It was found that α-ketoglutaric, pyruvic and succinic acids 
have a stimulatory effect on LP SME multiplication (p = 0.05) and initiation (p = 0.1 to 
0.14) at certain concentrations, when used alone or in combination (17). 
In this paper we report the results of a more direct approach for improving the 
composition of medium 1250 used in LP SE.  Here, we isolated a substance from early 
stage LP FG tissue that promotes SME growth; we then characterized this stimulatory 
substance as citric acid on the basis of 1H NMR and MS.  Finally, we demonstrated that 
topical application of 0.5 mM citric acid to early stage SMEs indeed stimulates colony 
growth for three genotypes at p = 0.05.  Moreover, we find that there is a good correlation 
between the amount of citric acid actually isolated from FG tissue (65 nmoles per stage 2 
or 3 FG) and the amount of topically applied citric acid that stimulates colony growth (25 
to 50 nmoles per SME).  The fact that an equivalent consistent stimulation of SME 
growth at p = 0.05 was not observed when 25 or 50 nmoles of citric acid was added 
directly to 1250 medium before or after autoclaving can be likely attributed to increased 
availability of iron to the growing embryogenic colony (24). 
In previous work, the amount of citric and isocitric acids in LP FG tissue was 
profiled by GC/MS and found to increase from stage 1 to 3, peak in mid-development 
and subsequently decrease from stage 7 onwards.  One FG of stage 3 was found to 
contain approximately 67 nmoles of these acids, which is in good agreement with our 
HPLC quantitation of citric acid in stage 2 or 3 FG (14).  Other research groups have 
investigated the role of citric acid in plant SE processes.  Nichol et. al. (1991) reported 
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that pre-treatment of RA-3 alfalfa callus with optimum concentrations of organic acids 
(K+- citrate [20 mM], K+-malate [60 mM], K+ +-succinate [less than 50 mM], K - tartarate 
[70 mM] or K+-oxalate [10 mM]) improved the yield and morphology of SMEs during 
the induction process without inducing embryogenesis per se (25).  Nichol et. al. (1991) 
found that substitution of citric acid by an appropriate chemical amount of other chelating 
or buffering reagents such as EGTA (ethylene glycol-bis(2-aminoethylether-N,N,N’,N’-
tetraacetic acid), EDTA or MES in the pre-treatment medium had no statistically 
significant effect on SME yield.  Hence he postulated that the mechanism by which these 
organic acids stimulated SE of RA-3 alfalfa was not dependent on buffering or chelation 
effects (25).  On the other hand, Malabadi and van Staden (2005) found that pre-
treatment with or incorporation into initiation medium of different ratios and 
combinations of citric and ascorbic acids, or tri-potassium citrate and citric acid caused a 
reduction in surviving cultures of three genotypes of Pinus patula and the number of 
SMEs produced (26).  Anthony et. al. (2004) carried out a similar study by adding tri-
potassium citrate and citric acid (0.01 % [w/v]) to induction medium of Conostephium 
pendulum after autoclaving and found that although the tissue necrosis was reduced, the 
treatment had no significant effect on the number of SMEs formed (27). 
There are a number of possible mechanisms by which citric acid could stimulate 
early stage SME growth.  In order to participate in the biochemical pathways of the 
rapidly growing SME, citric acid could enter the plant cell and various organelles within 
via the tricarboxylate electroneutral transporter or an organic acid carrier (28).  A 
proportion of citric acid that enters the somatic embryo cell is expected to participate in 
the mitochondrial citric acid cycle, which in turn has a direct impact on the energy 
production in the growing embryogenic mass.  The flow of citric acid through in the 
glyoxylate pathway of the glyoxisome is also plausible, which impacts the supply of C4 
molecules involved in nitrogen assimilation, gluconeogenesis, photo-respiration, fatty 
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acid biosynthesis and other biologically important pathways in the cell (29).  Citric acid 
could also participate in the production of cytosolic isocitrate via aconitate hydratase, and 
thereby affect production of glutamate and glutamine via 2-oxoglutarate.  Cytosolic 
NADPH produced during this process has a direct impact on the activity of various 
dehydrogenase enzymes and hence important biosynthetic pathways of SME. 
The direct involvement of citric acid as a source of energy to the growing early 
stage SMEs is supported by the fact that other acids from the citric acid cycle – pyruvic, 
succinic and α-ketoglutaric at respective concentrations of 0.52 mM, 0.125 mM and 0.68 
mM in the media - were all found to be stimulatory to SME colony growth of 3 
genotypes at p = 0.05 (17).  In addition, in our hands, glutaric acid, which is structurally 
similar to α-ketoglutaric acid, but is not an intermediate in the citric acid cycle, was 
found to be non-stimulatory to SME growth at the two concentrations tested (p = 0.05). 
Citric acid is a multi-functional molecule, whose presence at different 
concentrations could change the transport of various chemical osmoticants across plant 
outer and inner organelle membranes, affect plant metabolism and hence synthesis / 
degradation of biologically important molecules, alter the ratio of metal ions available 
outside and inside of SME via chelation and in general have a direct effect on the charge 
balance of the medium and SME.  The fact that only specific concentrations of citric acid 
are stimulatory at p = 0.05 to SME growth suggests that there is a delicate balance of 
anions/cations, metabolites, chemical osmoticants and metal ions that would be 
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Development of an Assay to Measure L-Phenylalanine Concentration in 
Blood Plasma 
3 – 1: SUMMARY 
Phenylketonuria (PKU) is an autosomal recessive disorder caused by an impaired 
conversion of L-phenylalanine (L-Phe) to L-tyrosine (L-Tyr) typically resulting from a 
deficiency in activity of a hepatic enzyme L-phenylalanine hydroxylase.  The disease is 
characterized by an increased concentration of L-Phe and its metabolites in body fluids.  
A novel assay based on enzymatic-colorimetric methodology was developed in order to 
detect elevated concentrations of L-Phe in undeproteinized plasma of PKU patients via 
continuous spectrophotometric detection.  We report here on a comparison of L-Phe 
concentrations in undeproteinized plasma measured using the enzymatic-colorimetric 
assay with those in deproteinized plasma obtained on an amino acid analyzer, and in 
derivatized dried blood spot eluates measured by HPLC and MS/MS, respectively.  
Pearson correlation coefficients of 0.951, 0.976 and 0.988 were obtained when amino 
acid analyzer-measured L-Phe concentrations were compared with the enzymatic-
colorimetric -, HPLC - and MS/MS - measured values, respectively.  A Bland and 
Altman analysis revealed that mean L-Phe concentrations determined on an amino acid 
analyzer were on average 0.067 mM lower than values measured by our enzymatic-
colorimetric assay and 0.14 mM and 0.1 mM higher than values measured by MS/MS 
and HPLC analyses, respectively.  Therefore, L-Phe concentrations determined by our 
enzymatic-colorimetric assay method are indeed comparable to those determined on an 







3 – 2: INTRODUCTION 
L-Phenylalanine Hydroxylase (PAH): 
 The PAH gene (on chromosome 12) contains 13 exons and spans 90 kbases (1); 
and is known to code for a 2.4 kbase mRNA.  PAH from Homo Sapiens (HS) consists of 
452 amino acids (AAs) and exists as homotetramers (2).  PAH is a mononuclear non-
heme iron (II)-containing enzyme composed of an N-terminal regulatory, a catalytic and 
a C-terminal tetramerization domains (2-4).  PAH converts L-phenylalanine (L-Phe) to L-
tyrosine (L-Tyr) in the presence of an essential (6R,1R’,2S’)-6-(1’,2’-dihydroxypropyl)-
5,6,7,8-tetrahydrobiopterin (BH ) co-factor and O  as shown in Scheme 3 - 1.  BH4 2 4 is 
recycled back to its reduced form by the action of dihydropteridine reductase with NADH 
as a co-factor or formed via dihydrofolate reductase from quinoid 7,8-dihydrobiopterin.  
HS PAH is activated by Fe (III) to Fe (II) reduction, binding of substrate and 
phosphorylation of Ser 16 (regulatory domain) by cAMP-dependent protein kinase (5).   
  X-Ray crystallography data, mutagenic, radio-label and spectral studies reveal 
some insight into PAH mechanism of action, which is still poorly understood (5).  A 
plausible mechanism based on cumulative data from various research groups is depicted 
in Scheme 3 - 2 (5, 6).  Initially, the active site iron (II) atom has six coordinates in a 
square-pyramidal coordination to 3 H2O molecules, His290, His285 and Glu330 residues.  
An active site conformation shift occurs when BH4, L-Phe are bound near Fe (II), with a 
subsequent displacement of 2 H O molecules.  Next, the last H2 2O molecule is displaced 
by molecular O  with subsequent formation of a 4-peroxy-BH2 4 intermediate.  In the 
following step a heterolytic cleavage of the O-O bond in 4-peroxy-BH4 takes place with a 
concomitant formation of 4-hydroxy-BH4 and an activated oxygen intermediate.  In the 
final step of catalysis, L-Tyr and 4-hydroxy-BH4 are released, the latter rapidly 
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Hyperphenylalaninemia (HPA) is an autosomal recessive disorder resulting from 
an impaired conversion of L-Phe to L-Tyr, PAH is responsible for the disposal of 
approximately 75 % of L-Phe in the body.  In addition, tyrosine hydroxylase and 
tryptophan hydroxylase localized in brain tissue and adrenal glands can hydroxylate L-
Phe to L-Tyr but with a different catalytic efficiency to PAH (5).  HPA can be caused by 
a number of possible mutations (over 400) in the gene that encodes PAH (7).  This 
disorder is characterized by an increased concentration of L-Phe and its metabolites 
(phenylpyruvate, phenyllactate, phenylethylamine and phenylacetate) in bodily fluids (8).  
Scheme 3 - 3 shows the normal pathway of L-Phe catabolism via L-Tyr and the alternate 
route of phenylketone formation, which is a direct result of elevated L-Phe plasma 
concentrations.   
Persons with classic PKU show very high elevations of blood L-Phe levels 
frequently exceeding 20 mg/dL or 1.2 mM (9).  Affected individuals tolerate less than 20 
mg of dietary L-Phe per kg of weight a day in order to maintain plasma L-Phe 
concentrations at a safe level of 0.12 to 0.3 mM.  A partial deficiency in PAH activity 
results in non-PKU HPA, a lower concentration of blood L-Phe that occurs without 
phenylketone accumulation and is characterized by a tolerance for higher dietary L-Phe 
levels (10).  PKU, if left undiagnosed and untreated, results in mental retardation, 
microcephaly, delayed speech, seizures, eczema, impaired pigmentation, behavior 
abnormalities and other negative symptoms (11).  The accumulation of L-Phe in the 
blood is suspected to cause competitive inhibition of transport of other large, neutral AAs 
required for protein and neurotransmitter synthesis across the blood brain barrier, reduced 
synthesis and increased degradation of myelin and inadequate formation of dopamine, 
epinephrine and norepinephrine as shown in Scheme 3 - 4 (12, 13). But the relationship 































































Scheme 3 - 3: Catabolism of L-Phe Under Normal and Elevated L-Phe Concentrations 
Asc + O2
AscH. + H2O + CO2
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Scheme 3 - 4: Metabolism of L-Tyr 
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Methods to Quantify L-Phe Concentrations in Bodily Fluids of PKU patients: 
In the USA, newborn screening for PKU has been underway for nearly 40 years.  
According to the NIH Consensus Statement (NIHCS), approximately 1 out of 15,000 
neonates is born with PKU every year, while for non-PKU HPA the yearly incidence is 1 
out of 48,000 births (10).  In order to prevent the severe mental and physical symptoms 
associated with PKU, diagnosis and initiation of dietary treatment must occur before the 
child is 3 weeks of age.  Several PKU screening methodologies are widely used 
currently: the Guthrie card bacterial inhibition assay, an inexpensive and semi-
quantitative test (14); fluorometric analysis (15,16); amino acid analysis (PAA) (17); MS 
(18,19); HPLC (20); and enzymatic-colorimetric assays (ECA) (21-34).  Initial screening 
tests for elevated L-Phe typically yield significant numbers of false positive results, 
which could be due to improper dried blood spot (DBS) preparation, liver immaturity, 
protein overload and other factors.   Therefore, abnormal L-Phe and / or L-Tyr levels are 
confirmed using quantitative analysis of AAs and BH4 determination.  Further molecular 
genetic tests (mutation, sequence and linkage analyses; as well as mutation scanning) are 
then performed to distinguish infants with complete PAH deficiency from those with an 
impaired activity of PAH (HPA) (7, 10).  In 1 to 2 % of cases impaired PAH activity 
could be caused by abnormalities in biosynthesis and metabolism of BH4, termed 
malignant PKU.  Other experimental techniques developed to measure plasma Phe levels 
include NADH-detecting biosensor (35); capillary electrophoresis / ESI MS (36) and LC-
MS (37), the latter two methods can detect and quantify underivatized Phe.  Preliminary 
studies have been carried to evaluate the feasibility of non-invasive PKU / HPA diagnosis 
by measuring concentrations of L-Phe and creatine in urine photometrically and by a 







Treatment of HPA / PKU: 
The generally accepted goal of treatment of PKU and HPA is normalization of the 
blood L-Phe and L-Tyr levels and thus prevention of the severe symptoms associated 
with this disorder.  Dietary therapy is the current most commonly used method to 
establish metabolic control over L-Phe levels.  The response to medical therapy is 
monitored at specialized metabolic centers at varying frequencies depending on the age 
of the patient and individual policy.  Limited studies have demonstrated that age at 
treatment initiation for PKU and the level of metabolic control influence intellectual, 
cognitive and behavioral outcomes of individuals suffering from PKU (10).  Hence the 
development of a reliable home monitoring testing method is recommended (10).  
ECAs Used to Measure Blood L-Phe Concentrations: 
ECA has proven to be a reliable, easily automated, and sensitive method for 
measuring L-Phe in deproteinized plasma and dried blood spot (DBS) eluates of PKU 
patients (21-34) as shown in table 3 - 1.  Wendel et. al. (1989, 1990 and 1991) used PAD 
from Rhodococcus sp. Strain M4 (RM4) to formulate an enzymatic assay coupled with an 
intermediate electron acceptor system (2-[4-iodophenyl]-3-[nitrophenyl]-5-phenyl-2H-
tetrazolium [INT] / diaphorase) to accurately quantify plasma or DBS L-Phe levels within 
a broad concentration range of 0.03 to 1.2 mM.  Other research groups (24, 29) similarly 
employed PAD / co-factor coupled with various tetrazolium dyes and either enzymatic or 
chemical mediators to diagnose and monitor PKU or HPA.  Next, Porton Cambridge 
launched a commercial kit (Quantase) for neonatal PKU screening in DBS and plasma 
samples (25, 28, 30-32).  The Quantase assay requires a 30-minute pre-incubation step of 
the eluted DBS or deproteinized plasma sample with enzyme / co-enzyme mixture, prior 
to addition of colorimetric reagents and end point spectrophotometric measurements (25, 
28, 30-32).  The currently used enzymatic / colorimetric assays require deproteinization 
of plasma samples or elution and /or deproteinization of DBS, which takes 8 to 60 
minutes as shown in Table 3 - 1. 
    
Table 3 – 1: Summary of ECAs Developed in Other Laboratories 
 
Ref Enzyme Colorimetric Assay Spectroscopic Blood Sample Deproteinization AMR, 
source/ Constituents Method; Type; n; and / or Elution Comparison, R or 
co-factor λ of Detection Patient type Instrument Used Bland and Altman 
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23 None λ = 340 nm Plasma; PCA 0.05 to 2 mM; 
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/ NAD
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Neonates 












Tetrazolium salt / 
Intermediate electron 
acceptor 
λ = 570 nm Plasma, n = 30 PCA (15 mins) 0.2 to 1 mM; 
End Point DBS, n = 54 TCA (30 mins) HPLC, R = 0.995 




Table 3 – 1: Summary of ECAs Developed in Other Laboratories (Continued) 
 
26 RM4 PAD / 
NAD+
None λ = 340 nm 
End Point 
Plasma; 
n = 70 
Treated HPA 
PCA 
Cobas Fara II 
Centrifugal Analyzer
0.05 to 1.5 mM 
PAA, R = 0.996 










λ = 570 nm 
End Point (2 mins) 
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n = 50 
 
TCA (30 mins); 
LabSystems 
Multiscan Plus  
Microtiter Plate 
Reader 
0.036 mM to 2 mM 
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0.01 to 3.75 mM 
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Fluorescence, -ve bias 
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Multiscan MCC 349 
0.043 to 1.08 mM; 
















For instance, a standard protocol for sample preparation using the Quantase kit 
requires a 60-minute elution and deproteinization of DBS with 3 % (v/v) TCA (25, 28, 31 
and 32).  In 1994, a laboratory in Baden-Wurttemberg (Germany) changed from BIA to 
ECA methodology to screen neonate blood L-Phe levels.  Schulze et. al. (2002) used the 
PAD-based ECA to screen 423,773 neonate samples for HPA, non-PKU or PKU during a 
6-year period and found the number of false positives to be 0.23 % with no false 
negatives reported. 
This chapter describes the development of a novel ECA for measuring L-Phe 
concentrations in undeproteinized plasma samples.  The methodology described here 
relies on the L-phenylalanine dehydrogenase (EC: 1.4.1.20; PAD)-mediated oxidative 
deamination of L-Phe to phenylpyruvate with a concomitant reduction of NAD+ to 
NADH.  The amount of NADH produced is quantified via continuous spectrophotometric 
detection (a kinetic assay), where 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) is reduced to its water-
soluble formazan product in the presence of NADH and an electron mediator, 5-
methylphenazinium methyl sulfate (PMS) as depicted in Scheme 3 - 5.  
Formulation of Home-Monitoring Device: 
 A simple robust device for the determination of plasma L-Phe, which could be 
used by the patient at home, would greatly facilitate the ability of the patient, in 
consultation with his or her physician, to control the tissue L-Phe concentrations.  In the 
last decades analytical and clinical chemistry developed to a point where many useful 
analytical measurements can be made using relatively simple and inexpensive 
instrumentation, the most common example being the quantitative glucose measurement 
for diabetics (39).   
The present work describes the progress being made towards the formulation of a 
novel test strip for analysis of plasma L-Phe levels.  Preliminary studies have been 
























































Scheme 3 - 5. ECA shows PAD-catalyzed conversion of L-Phe to phenylpyruvate with a 
concomitant production of NADH, recycled back to NAD+ by MTS-PMS assay. 
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Przybylowicz et. al. (1976), as the basis for making a home-monitoring device (40).  The 
test strip is proposed to consist of two or three super-imposable layers in liquid contact 
with each other on a solid support as shown in Scheme 3 - 6.  The reagent layer would 
contain appropriate concentrations of immobilized ECA reagents buffered at an optimal 
pH, such that in the presence of detectable L-Phe concentrations the signal could be 
measured and quantified.  The spreading and / or reflecting layer would assist in uniform 
spreading of the analyte, penetration towards ECA layer, filtering of red blood cells 
(RBCs) and serve as the reflection surface in order to enable the quantitation of signal via 
reflection densitometry. 
The device should enable the patient suffering from PKU to adjust the diet 

















































Scheme 3 - 6.  Multi-layer film for L-Phe quantitation. 
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3 – 3: MATERIALS AND METHODS 
Materials: 
MTS was purchased from Promega (Madison, WI, USA).  3,5-Dibromo-L-tyrosine 
monohydrate; cellulose acetate; [2H ]-phenylalanine; HPLC-grade CH CH OH, CH4 3 2 3CN, 
CH OH; [2H3 4]-tyrosine; human serum (Type A/B); Hyflo Super Cel diatomaceous earth; 
L-Phe; L-Tyr; methylene blue, NAD+; NADH; n-butanolic HCl; PMS; S-
aminoethylcysteine (SAEC); sulfosalicylic acid (SSA), teleostean gelatin (Type A), TiO2 
powder (particle size of less than 5 μm) and Triton X-100 detergent were purchased from 
Sigma Aldrich (St Louis, MO, USA).  PAD from Sporosarcina urea (SU) was purchased 
either from Sigma Aldrich or ICN Biomedicals (Irvine, CA, USA).  Acetone, CH Cl2 2, 
D2O, Fisherfinest Premium Microscope Slides Plain (2.54 × 2.54 × 0.10 cm), glycine and 
xylenes were purchased from Fisher Scientific (Atlanta, GA, USA).  TiO2 (particle size 
of 30 nm) was obtained from Alfa Aesar (Ward Hill, MA, USA).  Monobasic potassium 
phosphate, TiO2 anatase powder (200 nm particle size) and triethanolamine were 
obtained from Acros Organics (Norcross, GA, USA).  Quality control DBS standards 
(QCS spotted with 0.0025, 0.005, 0.01, 0.02 and 0.08 mM L-Phe or L-Tyr) were obtained 
from the Center for Disease Control (CDC) (Atlanta, GA, USA).  AccQ-Fluor reagent kit 
and AccQ-Tag column (150 × 3.9 mm) were purchased from Waters (Milford, MA, 
USA).  Schleicher & Schuell 903 (S&S 903) filter paper was obtained from Schleicher & 
Schuell, Inc. (Keene, NH, USA).  Beckmann Coulter’s Lithium buffers A, B, D, E and F; 
Beckmann high performance cation exchange column (0.4 × 10 cm), and ninhydrin were 
obtained from Beckmann Coulter (Fullerton, CA, USA).  Bird type film applicators (4 
and 8 mil), Gardco wire-wound rods (40 and 80 mil) and Leveling Drawdown Plate were 
purchased from Paul N. Gardner Inc. (Pompano Beach, FL, USA).  Polyethylene 
terephthalate (PET) was obtained from Goodfellow Corporation (Oakdale, CA, USA).  
Aluminum mold was manufactured at the Georgia Tech Machine Shop.  USB2000-FLG 
Spectrofluorometer (380 to 1050 nm), tungsten halogen light source (360 nm to 0.002 
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mm), reflection / backscattering probes and RPH-1 probe holder were purchased from 
Ocean Optics (Dunedin, FL, USA).  Spin coater WS-400B-6NPP-LITE was from Laurell 
Technologies (North Wales, PA). 
PAD Enzyme Activity Assay:
+In a 3 mL quartz cuvette 10 mM L-Phe, 3 mM NAD  and 0.002 to 0.008 units of 
PAD were combined together at 30oC in 192 mM glycine buffer (pH 10.5) and changes 
in absorbance at 340 nm (ΔA340) monitored using an HP 8453 diode array 
spectrophotometer equipped with an HP 8909 temperature-control accessory (n = 3).  The 
assay procedure was repeated in the absence of PAD (n = 3).  Initial ΔA340 was calculated 
using the kinetics module of the Biochemical Analysis UV-visible ChemStation software.  
The enzyme activity in U/mL was calculated as follows, when a 0.1 mL aliquot of PAD 
was added to give a final volume of 3 mL: 
U/mL PAD = [(ΔA340 w/ PAD - ΔA340 w/o PAD) × 3 × DF] / (6.22 × 0.1), where DF = 
dilution factor of PAD and 6.22 is the millimolar extinction coefficient (ε340) of NADH. 
Investigation of ECA: 
oAll subsequent experiments were conducted at 25 C unless otherwise indicated. 
Experiment 1: Effect of MTS and PMS on ECA 
+  0.06 mM MTS or 0.04 mM PMS, 0.06 mM L-Phe, 0.75 mM NAD and 0.1 U/mL 
PAD were combined together in pH 8.6 buffer and ΔA340 monitored.  A control assay 
was performed in the absence of MTS and / or PMS. 
Experiment 2: Effect of pH on NADH Oxidation by MTS and PMS 
 0.06 mM MTS; 0.04 mM PMS, and 0.012 mM, 0.03 mM or 0.06 mM NADH in 
198 mM glycine buffer (pH 10.5) were combined together and ΔA340 and ΔA550 
monitored.  A control assay was performed in the absence of NADH.  The observed shift 





Experiment 3: Determination of the Rate-Limiting Step in the ECA 
Enzymatic Assay:  0.012 mM, 0.06 mM or 0.12 mM L-Phe; 0.75 mM NAD+, and 0.1 
U/mL PAD were combined together in 5.4 mM potassium phosphate / 43 mM 
triethanolamine buffer (pH 8.6 buffer) and production of NADH monitored at 340 nm.  A 
control assay was performed in the absence of PAD.  
Colorimetric Assay:  0.06 mM MTS, 0.04 mM PMS and 0.06 mM NADH were 
combined together in pH 8.6 buffer, and NADH and formazan production monitored at 
340 nm and 490 nm, respectively.  A control assay was performed in the absence of 
NADH. 
Experiment 4: Effect of L-Tyr and Phenylpyruvate on ECA (0 to 0.3 mM L-Phe) 
 0.3 mM MTS; 0.15 mM PMS; 0.75 mM NAD+; 0.05, 0.15 or 0.3 mM L-Phe, 0.1 
mM L-Tyr and 0.17 U/mL PAD were combined together in pH 8.6 buffer and ΔA490 
monitored.  A control assay was performed in the absence of L-Tyr.  It should be noted 
that L-Tyr at appropriate concentrations can function as a substrate of SU PAD at pH 8.6 
(41).  However, when the enzymatic reaction is coupled to the colorimetric assay, we find 
that 0.1 mM L-Tyr does not compete with oxidation of L-Phe.  The procedure above was 
repeated except that L-Phe was used at a concentration of 0.125 mM or 0.275 mM and L-
Tyr was substituted with 0.004 mM or 0.02 mM phenylpyruvate. 
Experiment 5: ECA in 0 to 0.3 mM L-Phe Concentration Range 
0.3 mM MTS, 0.15 mM PMS, 0 to 0.3 mM L-Phe, 0.75 mM NAD+ and 0.17 
U/mL PAD were combined together in pH 8.6 buffer and ΔA490 monitored.  A control 
assay was performed in the absence of L-Phe.  Two measurements for each L-Phe 
concentration were made per run, and each run repeated over 3 days.  Initial ΔA490 (over 
60 seconds) was calculated and plotted against L-Phe concentration to obtain a 
calibration curve of y = 0.0017 (0.0014 to 0.0019) + 0.02 (0.019 to 0.021) × x with n = 
39, R = 0.98, standard deviation of residuals (SR) = 0.00042 and limit of quantitation 
(LOQ) = 0.069 mM.  Linear regression analysis was performed using Microsoft Excel 
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(2003), where values in parentheses represent lower and upper limits of either slope or 
intercept values at p = 0.05.  LOQ was calculated as shown: LOQ = 3.3 × SR / slope of 
regression equation. 
Experiment 6: Compare Effects of Serum and Plasma on ECA  
0.3 mM MTS; 0.15 mM PMS; 0.075, 0.125 or 0.2 mM L-Phe - spiked serum or 
plasma sample; 0.375 mM NAD+, and 0.17 U/mL PAD were combined in pH 8.6 buffer 
and ΔA520 monitored.  A control assay was performed in the absence of L-Phe - 
containing serum or plasma sample. 
Measurement L-Phe Concentrations in Plasma Samples of PKU Patients Using a 
Microplate Reader: 
Patient Selection:  Twenty five and 22 samples, respectively, of whole blood were 
collected in heparinized containers from patients at the beginning (6/21/04) and end 
(6/26/04) of “PKU camp” held at Emory University School of Medicine (Atlanta, GA).  
The methodology for blood collection was carried out in accordance with ethical 
standards of the Responsible Committee in Human Experimentation.  All participants in 
the camp were females, diagnosed with PKU.  Twenty participants were in the 12 to 18 
years age - group and 5 participants were in the 18 to 48 years age - group. 
DBS Preparation:  DBS were prepared by the finger-prick method, where each S & S 
903 filter paper was saturated with whole blood from a patient and air-dried at ambient 
temperature.  
Calibration Curve:  Fifty μL of ECA mixture was combined with 50 μL of L-Phe-
spiked serum and ΔA510 monitored using a Molecular Devices Thermomax microplate 
reader.  The final concentrations of reagents were as follows 0.2 mM MTS; 0.025 mM 
PMS; 0.37 mM NAD+; 0.23 U/mL PAD; and 0.06, 0.1, 0.15, 0.2, 0.25, 0.3 L-Phe in 2.7 
mM potassium phosphate / 21.4 mM triethanolamine buffer (pH 8.6).  Five to 7 
measurements for each concentration were performed per run and each run was repeated 
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on 4 different days.  Initial ΔA510 (over the first 300 seconds) was plotted against L-Phe 
concentration to obtain a calibration curve with a typical equation of y = 0.00019 
(0.00018 to 0.00021) + 0.00064 (0.0006 to 0.00068) × x with n = 42, R = 0.98, SR = 
0.000025 and LOQ = 0.13 mM.  
Each blood sample was centrifuged for 5 minutes at ambient temperature using a 
table-top IEC-HS centrifuge.  Platelet-rich plasma (PRP) was separated from red blood 
cell mass, and either analyzed by ECA or stored at – 20oC.  Three to 7 measurements for 
each fresh or frozen / thawed plasma sample were made in each run and the 
accompanying calibration curve obtained on that day was used to determine the sample 
L-Phe level.  Several runs were carried out to determine pre- and post- “PKU camp” L-
Phe concentrations.  Depending on sample L-Phe concentration, 15 to 50 μL of PKU 
plasma was required for a single measurement. 
L-Phe Concentration Determination in Deproteinized Plasma by PAA: 
 400 μL plasma sample was deproteinized with an equal volume of 6 % (v/v) SSA, 
centrifuged and the supernatant diluted with 500 μL of Lithium B buffer and 100 μL of 
0.25 mM SAEC (17).  PAA (AMR [Analytical Measurement Range]: 0.00625 mM to 
2.00 mM) was performed on a Beckman 6300 AA analyzer equipped with an in-line 
colorimetric detector.  The sample was applied onto a Beckman column and AAs 
separated using a combination of Beckman Coulter’s Lithium buffers A, D, E and F (pH 
range: 2.9 - 3.9).  The eluent was mixed with ninhydrin and absorbance measured at 570 
nm and 440 nm, respectively.  The Beckman Gold analysis software was used to identify 
and quantify AAs based on retention time and absorbance values with respect to that of 
calibration standards.  One measurement was performed for each plasma sample and pre- 
and post- “PKU” specimen were analyzed on two separate days. 
L-Phe Concentration Determination in DBS by HPLC: 
 A 3 mm diameter circle was punched out from the center of DBS on S&S 903 
filter paper from a PKU patient or a QCS and eluted with 50 μL of 70 % (v/v) 
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CH CH OH containing 5 μM (Br)3 2 2 L-Tyr for 20 minutes via sonication (42-44).  After 
centrifugation, 20 μL of the supernatant was derivatized with AccQ-Fluor reagent at 55oC 
for 10 minutes (22-24).  HPLC analysis (AMR: 0.008 mM to 0.250 mM) was performed 
using a Waters 2690 separations module equipped with a Waters 2475 fluorescence 
detector.  The analyte was applied onto a Waters AccQ-Tag column and eluted at 1 
mL/min or 0.5 mL/min using a mobile phase system consisting of AccQ-Tag eluent 
concentrate (A)/ CH3CN (B) / H2O (C) at 37oC.  The emission and excitation 
wavelengths were set at 250 and 395 nm, respectively.  Two runs per patient sample were 
carried out on the same day and pre- and post- “PKU camp” plasma analyzed on two 
separate days.  
L-Phe Concentration Determination in DBS by MS/MS: 
A 3 mm diameter circle was punched out from the center of DBS on S&S 903 
filter paper or QCS and eluted with 100 μL of CH3OH, containing stable isotope labeled 
AAs for 20 minutes via sonication (18, 45).  After solvent evaporation, AAs were 
esterified using 3 N n-butanolic HCl at 65oC, dried again and redissolved in 80% (v/v) 
CH3CN (18, 45).  MS/MS analysis (AMR: 0.021 mM to 0.20 mM) was performed on a 
Micromass Quattro Micro.  TIS capillary voltage was held at 3.5 kV, the cone voltage at 
35 V and the collision energy at 25 V (the collision gas was Ar).  MS/MS analysis used 
MS/MS scan of a neutral loss of 102 and data analysis performed with Neolynx software.  
Two runs per patient sample were conducted on the same day and pre- and post- “PKU 
camp” plasma analyzed on two separate days. 
Statistical Analysis of ECA, HPLC, MS/MS and PAA Data: 
 Intra-day run comparison of L-Phe concentrations in undeproteinized plasma 
samples measured by ECA were carried out using a Student’s t-test for paired means at p 
= 0.01.  Between run comparisons were carried out by computing the standard deviations 
for the mean L-Phe concentration in each sample in a given run.  Pearson correlation 
coefficients were computed using data collected by ECA, PAA, HPLC and MS/MS 
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methodologies.  Bland and Altman plots were used in further comparisons of the ECA, 
MS / MS and HPLC data to that obtained by PAA. 
Microplate ECA with Immobilized Reagents: 
An immobilized ECA mixture was prepared by dissolving teleostean gelatin upon 
heating.  ECA components were added to the cooled gelatin mixture.  First, 35 μL of 
gelatin was poured per well of a microplate and dried under a steady stream of air (the 
final pH of the ECA was 7.0).  Thirty five μL of L-Phe buffered at pH 8.6 was added to 
an ECA–containing well and ΔA510 monitored.  The final concentrations of ECA reagents 
were 0.15 mM MTS, 0.075 mM PMS, 0.75 mM NAD+, 0.13 U/mL PAD, 0.085 mg/μL 
gelatin, 0.05 mM to 10 mM L-Phe and 2.7 mM potassium phosphate / 21.5 mM 
triethanolamine buffer.  A control assay was performed in the absence of PAD.  Initial 
ΔA510 (over the first 300 seconds) was plotted against L-Phe concentration to obtain a 
calibration curve using Microsoft Excel (2003) of y = 0.000016 × x + 0.00008 with n = 5 
and R2 = 0.98. 
Formulation of Test-Strip for Measuring L-Phe Concentrations 
Film Composition and Preparation: 
Experiment 1: Effect of pH, Presence of Gelatin, Buffer composition and MTS/PMS 
Ratio on ECA: 
 An ECA mixture was prepared by dissolving teleostean gelatin in buffer upon 
heating.  MTS, PMS, L-Phe, NAD+ were added to the cooled gelatin mixture and stirred 
vigorously in the presence or absence of Tritonr X detergent.  PAD was added to the 
ECA mixture and absorbance changes at 490 nm were monitored on an HP 8453 diode 
array spectrophotometer equipped with an HP 8909 temperature-control accessory at 3-
second intervals over a period of 300 seconds.  The control assay was carried out in the 
absence of gelatin in 5 mM potassium phosphate / 43 mM triethanolamine (final assay 
pH of 8.6).  The final concentrations of ECA reagents were 0.4 mM MTS, 0.05 or 0.2 
mM PMS, 0.375 mM NAD+, 0.15 U/mL PAD, 0.1 or 0.6 mM L-Phe, 0.11 mg/μL gelatin, 
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0.0005g/ml Tritonr X and 3.3 mM potassium phosphate / 26.1 mM triethanolamine 
buffer (pH 7.0) or 5 mM potassium phosphate / 43 mM triethanolamine (pH 7.5).  Note 
the presence of gelatin at the given concentration lowers pH of the ECA mixture by 0.9 
units. 
Experiment 2: Composition and Preparation of ECA, Filtering / Reflecting (FRL) and 
Spreading (SL) Layers by Manual Application: 
 Polyethylene terephthalate (PET) and Fisherfinest Premium microscope slides 
were used as film supports (Scheme 3 - 6).  The ECA layer mixture was prepared by 
dissolving teleostean gelatin in pH 8.6 buffer by heating, and upon cooling of the solution 
adding all or some ECA reagents (0.3 mM MTS, 0.15 mM PMS, 1.5 mM NAD+ and 0.4 
to 0.97 U/ml PAD) to 5.6 mM potassium phosphate buffer / 56 mM triethanolamine.  The 
final pH of the ECA mixture was 7.0.  Subsequently, the ECA mixture was placed on a 
solid support (laid flat on the leveling draw-down plate) and spread over the surface with 
uniform strength using a 4 mil Gardco rod.  The film (approximate wet thickness of 102 
μm measured with a Gardco depth gauge) was allowed to dry at 25oC in a dust-free hood 
overnight.  The dry thickness in 3 different areas of the same film was measured using a 
micrometer gauge (n = 9) and found to vary between 9.3 and 22.9 μm, with an average 
dry thickness of 16.5 μm.  Blank ECA layers were produced by excluding all reagents but 
gelatin, while control ECA layers were made by including all ECA reagents but PAD, the 
reaction ECA layers contained all the assay reagents.  The final amounts of ECA reagents 
in the volume of ECA layer that comes in contact with 10 μL of analyte are 1.4 mg 
gelatin, 2.4 nmol MTS, 0.12 nmol PMS, 0.012 μmol NAD+, 0.0029 to 0.0078 Units PAD, 
0.044 μmol potassium phosphate and 0.35 μmol triethanolamine.   
 FRL was prepared by evenly dispersing 1.2 g of TiO2 (particle size range of 1 to 5 
μm) in 5 ml of 3 % (w/v) cellulose acetate (CA) solution in acetone.  The mixture was 
then diluted to a total volume of 8 ml with a 1:1 mixture of acetone : xylenes.  This 
mixture was then placed on the solid support or ECA layer and spread uniformly over the 
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surface with a 8 mil Bird applicator and 4 or 8 mil Gardco applicator rod .  The film was 
allowed to dry at 25oC, in a dust-free hood. 
 SL was prepared by evenly dispersing 0.186 g CA, 0.015 g SSA and 1.8 g of 
diatomaceous earth in 1.2 : 1 mixture of CH Cl2 2 : acetone. The slurry was then placed on 
the solid support or ECA layer or FRL surface and spread out evenly with a 8 mil Bird 
applicator.  The film was allowed to dry at 25oC, in a dust-free hood.  
Experiment 3: Composition and Preparation of ECA, FRL and SL by Spin Coating 
 PET squares (2.54 × 2.54 cm) or VWR micro-cover glass (2.2 cm in diameter and 
0.23 mm in thickness) were used as film supports.  Two hundred μL of ECA-containing 
mixture was placed on the surface of the support and a film layer produced on a WS-
400B-6NPP-LITE spin coater via different methodologies.  The optimized spin coating 
method that produced the best results employed a standard acceleration and a 2-step 
procedure with a 1st step of 500 rpm (30 seconds) followed by the 2nd step of 1500 rpm (3 
minutes).  The ECA stock solution used to prepare the film contained 0.35 mg/μL of 
gelatin, 5 mM MTS, 0.625 mM PMS, 10 mM NAD+, 15 U/ml PAD in 10.5 mM 
potassium phosphate / 84 mM triethanolamine (pH 7.0).  The thickness of ECA layer was 
measured on a Zygo interferometer and found to be less than 50 nm, which is the LOD 
(limit of detection) of this particular instrument. 
 FRL mixture was prepared by dispersing 1.2 g of TiO2 (particle size of 200 nm 
and 30 nm) in 5 ml of 3 % (w/v) CA solution in acetone. The mixture was then diluted to 
a total volume of 8 ml with a 1:1 mixture of acetone : xylenes in the presence or absence 
of 0.063 % Tritonr X and stirred for 20 to 24 hours.  Two hundred μL of FRL mixture 
was subsequently placed either on ECA layer or solid support and the film formed on a 
WS-400B-6NPP-LITE spin coater via different methodologies.  The best results were 
obtained with 1.2 g TiO2 of 200 nm particle size, presence of detergent in FRL aided the 
wettability of the film but didn’t improve the analyte spreading.  Several spin coating 
methods with standard acceleration were employed to make single, double and triple 
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filtering / reflecting layers.  Spin speeds of 500, 1000, 1500, 2500 or 5000 rpm were 
employed with a deposition time of 1 to 1.3 minutes, identical or different spin speeds 
were used in the formation of a double or triple layer films.  The uniformity of single 
layer films produced with spin speeds of 500, 2000 or 5000 rpm were analyzed using 
electron microscopy.  The number of pinholes was minimized when intermediate spin 
speed was used.  The thickness of one - layer films made at spin speeds of 2000 or 3000 
rpm for 1 minute was analyzed on the Tencor Alpha-Step Profilometer.  The results 
showed that uneven films of 2 to 5 μm at faster speeds and 10 to 12 μm at slower speeds 
were produced, some pinholes on film surface were 20 μm in diameter. 
 SL was prepared by evenly dispersing 0.375 g CA, 0.015 g SSA and 1.5 g of 
diatomaceous earth in 1.2 : 1 mixture of CH Cl2 2 : acetone with or without a small 
quantity of Tritonr X detergent.  The slurry was then placed on the solid support or ECA 
layer or FRL surface and the film formed on a WS-400B-6NPP-LITE spin coater via 
different methodologies.  The best results were produced with a spin speed of 1000 rpm 
for 1.3 minutes and standard acceleration.  
Experiment 4: Composition and Preparation of ECA, FLR and SL by Solvent Casting 
 Finally, the most successful ECA layers were prepared using an Aluminum mold 
(inner diameter of 2.54 cm).  Various volumes of ECA mixture (350, 400 or 600 μL) 
were placed in the mold secured on top of the PET support with vacuum seal grease and 
allowed to dry under a steady stream of cool air in a dust-free hood at 25oC.  The best 
results were obtained with a 350 μL ECA volume.  The concentrations of the reagents in 
the assay mixture were as follows: 108 mg/ml teleostean gelatin, 1.05 mM MTS, 0.26 
mM PMS, 5.4 mM β-NAD+, 2.3 U/ml PAD and 3.3 mM potassium phosphate/ 26.1 mM 
triethanolamine buffer (final pH 7.1).  The final amounts of ECA reagents in the volume 
of ECA layer that comes in contact with 10 μL of analyte (considering it spreads to an 
average diameter of 1.0 cm) are 7.4 mg gelatin, 72.4 nmol MTS, 17.94 nmol PMS, 0.37 
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+μmol NAD , 0.16 Units PAD, 0.23 μmol potassium phosphate and 1.8 μmol 
triethanolamine. 
FRL mixture was prepared by dispersing 0.6 g, 0.9 g, 1.2 g 1.5 g, 1.8 g or 2.1 g of 
TiO2 (particle size of 1 to 5 μm or 200 nm or 30 nm) in 5 ml of 3 % (w/v) CA solution in 
acetone. The mixture was then diluted to a total volume of 8 ml with a 1:1 mixture of 
acetone : xylenes in the presence or absence of 0.063 % Tritonr X.  One hundred and 
fifty, 200, 300, 400 or 600 μL FRL was subsequently poured either onto PET or ECA 
layer within the well of the mold and allowed to air-dry at 25oC.  The best films (minimal 
cracking or peeling) were obtained using 400 μL of FRL mixture made with 1.2 g TiO2 of 
30 nm particle size. 
SL was prepared by evenly dispersing 0.375 g CA, 0.015 g SSA and 1.5 g of 
diatomaceous earth in 1.2 : 1 mixture of CH Cl2 2 : acetone.  Two hundred, 300, 400 or 500 
μL SL was then poured onto PET or ECA layer within the mold and allowed to air-dry at 
25oC. 
Measurements Carried Using the Portable Ocean Optics Spectrometer Equipment: 
The fiber optic cable connected to the halogen light source was placed in the 45o 
angle slot of the probe holder, while the fiber optic connected to the detector was placed 
in the 90o angle slot.  The integration time was adjusted such that the recorded signal 
intensity was between 3200 and 3500 intensity counts when the film was placed on the 
probe holder with PET underside facing the light source and detector.  The ‘dark’ reading 
was taken at the set integration time when the light source and detector were completely 
covered.  The ‘reference’ reading was taken when the film was placed in the path of the 
light source with no analyte added to the surface.  Subsequently, 10 μL drop of pH 8.6 
buffer or L-Phe (0.5, 1 or 20 mM buffered at pH 8.6) or plasma (diluted with pH 8.6 in a 
1:1 ratio) or serum (diluted with pH 8.6 buffer in a 1:1 ratio) was placed on the surface of 
the ECA or FR or SL layer, the liquid spread over an area approximately 10 mm in 
diameter in the absence of Tritonr X detergent.  In the absence of FRL or SL, a polished 
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Teflon surface was placed on top of the spreading and % reflectance measured at various 
time intervals (10 to 30 sec) over a period of 600 seconds in transmittance mode at 490 
nm. 
In order to investigate the speed with which an aqueous analyte penetrated FRL 
(prepared in the absence or presence of 0.063 % (v/v) Tritonr X detergent), a 5 or 10 μL 
drop of 1.2 mM methylene blue was placed on FRL and % reflectance measured at 40 
second intervals over a period of 600 seconds at 610 and 670 nm respectively.  The 
presence of detergent in FRL caused irregularity in analyte spreading. 
Testing the Sensitivity of the Ocean Optics Detector Cable: 
 A color pallet of varying intensities (0 to 10 % printed on Epson Styles Color 880 
Color Ink Jet printer) was prepared by Charlie Oldham using CoralDRAW (Version 12).  
The integration time was adjusted as described above for 0 % magenta, ‘dark’ and 
‘reference’ readings taken in scope mode at the set integration time.  The spectra were 
















3 – 4: RESULTS 
Selection of Reagents for the Enzymatic-Colorimetric Assay: 
SU PAD was chosen as the enzyme for our ECA due to its high degree of 
specificity for L-Phe as a substrate and its commercial availability (41).  Table 3 - 2 
compares the specificity, stability, ease of inactivation with inhibitors and other 
parameters of PAD from Rhodococcus sp. M4 strain (RM4) and Sporosarcina ureae (SU) 
(46).  According to the research studies conducted thus far, SU PAD is more specific than 
RM4 PAD but is more susceptible to inactivation by various chemicals.  Asano et. al. 
reported that SU  PAD was stable for at least 1 month when stored at 4oC in 10 mM 
potassium phosphate buffer (pH 7.0), 0.1 M EDTA and 5 mM 2-mercaptoethanol, and for 
a period of 2 years when stored in crystalline form (41).  We investigated the stability of 
PAD over a 40-day period under different storage conditions (refrigerated or frozen 
solution, or lyophilized powder).  Assay data indicated that loss of activity was 
minimized when PAD was stored lyophilized in the presence of 50 mM potassium 
phosphate (pH 7.0) at – 20oC, with no additional stabilizing agents that might interfere 
with the ECA. 
Tetrazolium dyes and Mediators: 
Tetrazolium salts are readily reduced chromogenic dyes that generate formazan 
dyes.  These salts are widely used to measure cell proliferation and viability (extra 
cellular and intracellular dehydrogenase / oxidoreductase activity), in cytotoxicity assays, 
histochemical procedures and bacteriological screening (respiration) (47).  Typically, a 
tetrazolium dye (MTS, MTT, NBT, XTT or WST-1– 8) is reduced by an electron 
mediator or directly by NADH or NADPH, formed from a NAD+ or NADP+ precursor 
involved in the reaction of the dehydrogenase enzyme and its substrate.  Unfortunately 
some formazan dyes, such as MTT, have poor water solubility and hence cause 
precipitation during spectrophotometric detection in a certain concentration range.   
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Table 3 - 2: Comparison of PAD from 2 Different Sources 
PAD from PAD from 
 Rhodococcus sp M4 strain Sporosarcina ureae 





















































































Table 3 - 2: Comparison of PAD from 2 Different Sources (Continued) 































































































































Table 3 - 2: Comparison of PAD from 2 Different Sources (Continued) 
 
pH 9.3 (reductive amination) 9 to 10.3 (reductive amination) 




20o oC 40 C 
Molecular 150 KDa (gel filtration) 305 KDa (sedimentation) 


























The use of water-soluble dyes (XTT and WST-1) is therefore advantageous.  Unlike 
MTT; XTT, MTS and WST-1 are efficiently reduced by NADH and NADPH in the 
absence of cells or enzymes but in the presence of electron mediators such as PMS, 
MPMS (1-methoxy phenazine methosulfate), PES (phenazine ethosulfate) or MB (8-
dimethylamino 2,3-benzophenoxazine) and the reduction process involves superoxide 
(47).  Unfortunately, the mechanism of bioreduction of tetrazolium dyes such as MTS has 
not been fully elucidated (47).  The ability of tetrazolium dyes to penetrate plasma 
membranes without irreparably damaging the cell, is an important parameter in dye 
selection.  Plasma-membrane permeable tetrazolium derivatives (MTT) can undergo 
reduction intra- and extra-cellularly.  On the other hand, plasma membrane-impermeable 
tetrazolium derivatives (CTC [5-cayno-2,3-ditolyl tetrazolium chloride], WTS-1) are 
separated from reducing species located in the cell interior, hence their bioreduction can 
be carried out by plasma membrane associated reductases or long-lived reducing species 
capable of diffusing out of cells (47, 48).  The membrane permeability of MTS has not 
been investigated, but it would be relevant to the function of ECA, because it is designed 
to measure extra-cellular levels of plasma L-Phe.  
 The MTS-PMS dye-mediator combination was found to be optimal for our ECA, 
which is depicted in Scheme 3 - 5.  The regeneration of NAD+ in the presence of MTS 
and PMS is facile, occurs in a stoichiometric manner, is accompanied by a distinct color 
change, and both oxidized and reduced forms of MTS are H2O-soluble under the ECA 
conditions.  The UV-Visible spectra of MTS and PMS components before and after 
reduction by NADH are shown in Figure 3 - 1.  Upper panel of Figure 3 - 2 shows that 
PAD-catalyzed conversion of limiting L-Phe concentrations (0.012 mM, 0.06 mM or 
0.12 mM) to phenylpyruvate is proportional to L-Phe concentration although the reaction 
is incomplete after 30 minutes as indicated by the stoichiometry of NADH production 












































Figure 3 - 1. Overlaid absorbance spectra of 0.06 mM MTS and 0.04 mM PMS in the 





















































Figure 3 - 2. Upper Panel: Three mL of enzymatic assay contains 0.75 mM NAD+; 0.012 
mM (●), 0.06 mM (□) or 0.12 mM (▲) mM L-Phe and 0.10 U/mL PAD in pH 8.6 buffer.  
Lower Panel: Three mL of colorimetric assay contains 0.06 mM MTS, 0.04 mM PMS 
and either 0 mM (340 nm [▲] and 490 nm [■]) or 0.06 mM (340 nm [Δ] and 490 nm [□]) 
NADH in pH 8.6 buffer. 
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that 0.06 mM NADH completely reacts with an equivalent amount of MTS in the 
presence of  PMS within 60 seconds, thus demonstrating that the PAD-catalyzed reaction 
is the rate-determining step in ECA at low L-Phe concentrations. 
The effects of changing the concentrations of ECA components were 
systematically investigated.  Within 0 to 0.3 mM L-Phe concentration range, 0.06 mM 
MTS was found to have no inhibitory effect on PAD activity.  In addition, L-Tyr did not 
interfere with function of ECA; 0.1 mM L-Tyr used is on the high end of concentration 
range anticipated to be present in plasma of PKU patients.  ECA was carried out at pH 
8.6 and not pH 10.5 which is optimal for PAD activity, because the rate of spontaneous 
formazan formation increases with increasing pH (49); at this lower pH, the activity of 
PAD was reduced by a factor of 2.7. 
Blood L-Phe concentration of PKU patients can exceed 1.2 mM, with the 
reference clinical range for L-Phe at 0.078 to 0.206 mM depending on the age of the 
individual (50).  A linear dependence of the rate of change of absorbance at 490 nm for a 
broad range of L-Phe concentrations (from 0 to 2400 μM) was obtained, when the 
concentrations of ECA reagents were adjusted as described in the MATERIALS AND 
METHODS.  The best results were obtained for 0 to 0.3 mM L-Phe concentration range 
with a regression equation of y = 0.0017 (0.0014 to 0.0019) + 0.020 (0.0186 to 0.0214) × 
x (n = 39 and R = 0.98), which corresponds to a diluted range of 0 to 9 mM L-Phe.  The 
limit of quantitation (LOQ) was determined as described in the experimental section, and 
found to be 0.069 mM.  The accuracy of the curve was tested with standard samples 
containing known L-Phe concentrations, where % differences between determined and 
actual concentrations of L-Phe were 1.1 % for 0.11 mM L-Phe and 5.6 % for 0.175 mM 
L-Phe. 
[L-Phe] Determination in Serum and Plasma Samples Using the ECA: 
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The effect of serum components on ECA was investigated.  The presence of 
serum in ECA, filtered through a 0.45 μm membrane, caused a shift in λmax of the 
formazan dye from 490 to 520 nm.  Experiments were then carried out to investigate the 
effect of PRP– and serum- spiked L-Phe solutions on ECA.  Table 3 - 3 shows that initial 
ΔA520 were identical for serum- and PRP- containing ECAs at L-Phe concentrations of 
0.075 mM, 0.125 mM and 0.25 mM.  It is therefore evident that additional components 
present in plasma as compared to serum do not interfere with ECA function under the 
given reaction conditions. 
Whole blood samples were collected from 25 and 22 participants at the beginning 
and end of “PKU camp”, respectively.  During the week of camp, the patients were 
placed on a diet consisting of low Phe protein products enriched with Tyr.  PRP was 
prepared from whole blood and L-Phe concentration in each sample determined by our 
ECA as described in the MATERIALS AND METHODS.  Figure 3 - 3 shows a typical 
calibration curve used to determine L-Phe concentration in each sample, with typical R 
values in such graphs ranging from 0.93 (n = 47) to 0.98 ( n = 42) with a mean LOQ of 
0.07 mM.  At least two L-Phe concentration measurements were made in a given run per 
patient sample, and runs repeated over a number of days.  Figure 3 - 4 shows within run 
variation in mean L-Phe concentrations measured by ECA in pre- and post- “PKU camp” 
samples (Upper Panel).  Mean sample L-Phe concentrations measured in separate runs 
were compared using Student’s t-test for paired means and found to be statistically 
equivalent at p = 0.01 in all but one inter-run comparison.  Overall average L-Phe 
concentrations at the beginning and end of “PKU camp” for each participant were 
subsequently determined, and correlation with the diet the subjects were placed on 
depicted in Figure 3 - 4 (Lower Panel).  It is evident that for most PKU patients with 














Table 3 - 3: Effect of Serum and Plasma on ECA Compared  
Rate of Change of Absorbance (AU/sec) 
 [L-Phe] = 0 μM [L-Phe] = 75 μM [L-Phe] = 125μM [L-Phe] = 250μM 
 
Serum 0.0011 0.0023 0.0030 0.0036 
 

















































































Figure 3 - 3. A calibration curve used to determine plasma L-Phe concentration of PKU 
patients obtained as described in the experimental section.  The regression equation for 
the calibration curve is y = 0.0013 (0.0012 to 0.0014) × x + 0.00018 (0.00016 to 0.00019) 































































Figure 3 - 4. Upper Panel: Inter- and intra- run comparison of mean plasma L-Phe 
concentrations measured by ECA, each bar represents run average per sample measured 
at the beginning (█) and end (□) of “PKU camp”.  Lower Panel: Average L-Phe 
concentrations in pre- (█) and post- (□) PKU camp samples.  Dietary Tyr/Phe per kg of 




Comparison of our ECA to Other Techniques Used to Monitor PKU: 
Three other techniques were used to measure L-Phe levels in plasma and DBS samples 
from “PKU camp” participants: PAA, HPLC and MS/MS.  PAA was conducted on 
deproteinized plasma samples, while HPLC and MS/MS analyses were performed on 
derivatized DBS eluates as described in the MATERIALS AND METHODS section.  
Table 3 - 4 and Figure 3 - 5 show that the ECA results correlated reasonably well with the 
data obtained by PAA with a Pearson correlation coefficient R = 0.951 at n = 47 and p < 
0.0001.  R values within a similar range were obtained when L-Phe concentrations 
determined by PAA were compared with results of HPLC and MS/MS analyses with R = 
0.976, and R = 0.988, respectively.  Tables 3 - 5 and 3 - 6 show that ECA results 
collected with the pre-‘PKU’ camp plasma samples had a higher Pearson correlation 
coefficient with PAA data of 0.961 than post-‘PKU’ camp data with R values of 0.926. 
ECA-, HPLC- and MS/MS- measured L-Phe concentrations were then compared 
with values determined by PAA using Bland and Altman plots.  Figure 3 - 6 shows that 
L-Phe concentrations measured by PAA are on average 0.065 mM lower than values 
measured by ECA and on average 0.14 mM and 0.10 mM higher than those measured by 
MS/MS and HPLC analyses.  Higher ECA-determined L-Phe values could be the result 
of minimizing the manipulations carried out on the patient sample in comparison to PAA, 
HPLC and MS/MS methods, which involve plasma deproteinization or DBS eluate 
derivatization and if needed deproteinization (50, 51).  In addition, Figure 3 - 6 shows 
that differences between individual L-Phe values determined by either HPLC or MS/MS 
and PAA are smaller in the L-Phe concentration range of 0 to 0.80 mM.  A similar trend, 
which correlated L-Phe concentration range and differences in values measured by ECA 
and PAA was not observed.  Bland and Altman plots also show that the majority of the 
points are within 2 × SD ± d range, where SD represents the standard deviation of the 
mean difference (d) between L-Phe concentrations measured by PAA and either HPLC, 
















Table 3 - 4: Combined Pre- and Post- “PKU camp” Data 
Pearson Correlation Coefficients (n = 47, p < 0.0001) 
PAA HPLC MS/MS ECA  
PAA 1.000 0.976 0.988 0.951 
HPLC 0.976 1.000 0.980 0.905 
MS/MS 0.988 0.980 1.000 0.937 
































































Figure 3 - 5: Correlation plots of HPLC ,MS/MS-, ECA- measured L-Phe valu










Table 3 - 5: Pre - “PKU camp” Data 
Pearson Correlation Coefficients (n = 47, p < 0.0001) 
PAA HPLC MS/MS ECA  
PAA 1.000 0.988 0.983 0.961 
HPLC 0.988 1.000 0.995 0.948 
MS/MS 0.983 0.995 1.000 0.936 
ECA 0.961 0.948 0.936 1.000 
Table 3 - 6:  Post -“PKU camp” Data 
PAA HPLC MS/MS ECA  
PAA 1.000 0.922 0.991 0.926 
HPLC 0.922 1.000 0.915 0.784 
MS/MS 0.991 0.915 1.000 0.940 
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Figure 3 - 6. Bias plots of HPLC-, MS/MS-, ECA- measured L-Phe values as compared 
to PAA data. 
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Towards Home-Monitoring of L-Phe for PKU Patients:  
A home-monitoring device for PKU patients would likely entail a multi-layer format, 
where the first layer filters out blood cells from the sample, the next layer contains 
immobilized ECA reagents, which enable spectrophotometric detection of plasma L-Phe 
concentration.  Initial studies showed that ECA components function as expected when 
immobilized.  A typical reagent mixture was prepared as described in the 
MATERIALS AND METHODS section, a solution of L-Phe (buffered at pH 8.6) added 
to the dry ECA mixture buffered at pH 7.0 and ΔA510 monitored.  Figure 3 - 7 shows a 
calibration curve, based on preliminary results, for a broad L-Phe concentration range. 
 The effects of pH, presence of gelatin, Tritonr X detergent and MTS/PMS ratio 
were investigated via a spectrophotometric assay as documented in Table 3 - 7.  It was 
found that the presence of 0.0005 g/ml detergent or lower PMS concentration had no 
statistically significant effect on the results of ECA at pH 8.6 in the absence of gelatin 
with 0.1 and 0.6 mM L-Phe.  On the other hand, ΔA490 decreased when the composition 
of buffer was varied such that the final pH of the ECA in the presence of gelatin was 7.0 
instead of 7.5.   
Preliminary experiments have been carried out to make multi-layer films 
comprising ECA (ECA reagents in a gelatin matrix), filtering / reflecting (TiO2 particles 
of various sizes embedded in a cellulose acetate binder) and spreading layers 
(diatomaceous earth in a cellulose acetate binder) on a glass or PET solid support.  
Several methodologies have been employed to prepare these layers: manual application 
with Gardco Wire-Wound rods and Bird Type applicators, solvent casting and spin 
coating.  
In the case of ECA films, manual application with Gardco rods did not produce 
uniform films; however the appropriate thickness (low μm range) was obtained. On the 
other hand, spin coating via a two-step spin speed deposition technique produced more 





















































Figure 3 - 7. A calibration curve for 0 to 10 mM L-Phe range obtained with immobilized 
ECA as described in the MATERIALS AND METHODS.  The regression equation for 
the calibration curve is y = 0.000016 × x + 0.00008 with n = 5 and R2 = 0.98.  Inset is a 
digital image of the microplate containing immobilized mixtures with only gelatin 
(blank), all reagents and no PAD (control) and all ECA components with 0 to 10 mM L-








Table 3 - 7: Investigation of Immobilized ECA 
 pH 7.5 pH 7.0 pH 8.6 pH 8.6 pH 8.6 
0.11 mg/μl Gel 0.11 mg/μl Gel No Gelatin No Gelatin No Gelatin 
0.4 mM MTS 0.4 mM MTS 0.4 mM MTS 0.4 mM MTS 0.4 mM MTS 





0.375 mM NAD+ 0.375 mM  0.375 mM 
NAD
0.375 mM 
NAD0.15 U/ml PAD NAD+ + + 
0.15 U/ml PAD  0.15 U/ml PAD  0.15 U/ml PAD 
0.0005 g/ml 
Tritonr X  
ΔA 0.0019 0.0017 0.0016 - - 490 
0.1 mM  
L-Phe 
ΔA 0.0052 0.0055 0.0053 0.0015 0.00083 490 



























preparation methods inherently waste ECA reagents.  Some ECA reagents (such as MTS) 
have limited solubility in aqueous buffer at very high concentrations, and the Ocean 
Optics instrumentation used for reflectance measurements within the ECA layer has 
limited detection capabilities, hence the requirement for thicker ECA films.  Such thicker  
films were made by solvent casting, where a detectable signal could be measured with the 
Ocean Optics portable equipment in the presence of the analyte.  Optimal films were 
made with 350 μl of ECA mixture as described in the MATERIALS AND METHODS. 
In the case of filtering / reflecting layers (FRL) made by manual application, the 
best films were produced when 1.2 g of TiO2 (particle size range of under 5 μm) was 
suspended 3 % (v/v) binder and applied onto the ECA layer with a 8 mil Bird applicator.  
The films made in this manner weren’t analyzed by optical microscopy and the thickness 
could not be measured with a micrometer gauge due to the sensitivity of this layer to 
metal contact.   
Spin-coating methodology was next used to make FRL films, where the optimal 
TiO2 particle size, the time and extent of stirring of the FRL mixture, the presence of 
Tritonr X detergent and various spin coating methods (varied spin speeds, time of 
deposition, the number of steps in method and the number of depositions) were 
investigated in relation to the quality of the films produced.  Although greater degree of 
uniformity was obtained with spin coating vs. manual application, the desired thickness 
of FRL films wasn’t achieved via spin coating, and the porosity of the layer was non-
uniform.  The pore size on some of the best films produced using TiO2 of 200 nm particle 
size, standard acceleration and a single deposition method with a spin speed of 2000 or 
3000 rpm for 1 minute still had pore sizes of more than 10 μm, which means that this 
layer would not be capable of filtering out blood cells.  Film characterization (pore size 
and thickness) was carried out on the Tencor Alpha-Step Profilometer and an Optical 




Spreading layer (SL) films were primarily made using the 8 mil Bird applicator 
rod and an extensive investigation to make such layers by either spin coating or solvent 
casting method was not carried out. 
Preliminary experiments to investigate that these 2 or 3 layer films can detect 0.5 
to 20 mM L-Phe have been carried out, but the results obtained were not easily 
reproducible, primarily due to issues related to the non-uniformity of the films.  Figure  
3 - 8 shows that a 3-layer film prepared by manual application functions as expected, 
when a 10 μl drop of 20 mM L-Phe (pH 8.6) was placed on the SL surface.  However, the 
initial rate of change of absorbance is not linear. 
The films made by solvent casting were next used in further investigations.  The 
production of ECA films via solvent casting was successfully accomplished.  On the 
other hand, FRL films made via solvent casting tended to peel and crack upon drying 
when poured over the ECA films made by the same methodology.  The best results were 
obtained when 400 μl of 1.2 g of TiO2 (30 nm particle size) suspended in 3 % (v/v) 
cellulose acetate (CA) was used to make the film and was subsequently air-dried.  The 
most consistent and reproducible measurements were obtained when a polished Teflon 
surface was used in place of a FRL, since the latter still needs further optimization.  
Figure 3 - 9 shows that ECA layer made via solvent casting could detect a 1 mM L-Phe 
concentration (pH 8.6), as the initial rate of change of absorbance observed at 490 nm is 
higher than that observed for the same volume of pH 8.6 buffer.  A calibration curve for a 
range of L-Phe concentrations could not be obtained under the given experimental 
conditions due to the low reproducibility associated with these experiments.  The poor 
measurement to measurement reproducibility with the same ECA film could be attributed 
to low instrument sensitivity, uneven distribution of L-Phe over the surface of the film 
































































Figure 3 - 8.  Change of Absorbance at 490 nm measured with the Ocean Optics 
spectrometer when a 10 μl drop of 20 mM L-Phe (pH 8.6) was placed on the surface of a 
3-layer film, where ECA layer was made with a 40 mil Gardco applicator, and FRL and 
SL with a 8 mil Bird applicator as described in experiment 2.  Lines marked with: ◊ 
represent data collected with Blank ECA/ FRL/ SL film; □ represent data collected with 
















































Figure 3 - 9.  Change of Absorbance at 490 nm measured with the Ocean Optics 
spectrometer when a 10 μl drop of 1 mM L-Phe (pH 8.6) represented by □ or 10 μl drop 
of pH 8.6 buffer represented by ○ was placed on the surface of an ECA film prepared by 




3 – 5: DISCUSSION 
The generally accepted goal of treatment for PKU is normalization of L-Phe and 
L-Tyr plasma levels and thus prevention of the severe symptoms associated with PKU.  
Blood L-Phe levels in newborns should be brought within normal levels 3 weeks after 
their birth, hence the requirement for PKU neonatal screening (10).  If left untreated, the 
accumulation of high plasma L-Phe concentrations causes disruptions in protein 
metabolism and impaired brain development and function in PKU patients.  The direct 
cause of the severe symptoms associated with PKU is unknown but major contributing 
factors are: AA imbalance; elevated plasma and tissue L-Phe; transport inhibition of AAs 
across the blood brain barrier; white matter abnormalities; delays in the development of 
cerebral cortex; and interference with myelination (11, 52).   
The frequency of monitoring plasma L-Phe concentrations in PKU patients of 
different age groups varies from state to state in USA.  Plasma L-Phe level is measured 
once a week in patients less than 1 year of age, once a month during adolescence and 6 
months to a year in adults (10).  Women with a PAH deficiency must be careful to bring 
L-Phe levels under 0.3 mM during conception and gestation (53, 54).  Abnormalities that 
result from fetal exposure to elevated maternal plasma L-Phe concentrations include 
congenital heart disease, intrauterine and postnatal growth retardation, microcephaly and 
mental retardation (53, 54).  The Maternal PKU Collaborative Study reports that even at 
maternal plasma L-Phe concentrations of 0.12 to 0.36 mM, 6 % of infants are born with 
microcephaly and 4 % with postnatal growth retardation (54).  If maternal plasma L-Phe 
concentrations are higher than 0.9 mM, the risk increases to 85 % for microcephaly, 51 % 
for postnatal growth retardation and 26 % for intrauterine growth retardation. 
Currently, the most common approach used to keep L-Phe levels under control in 
PKU patients is the use of modified protein products, which provide required amounts of 
L-Phe and L-Tyr (55).  The response to dietary therapy is monitored via measurement of 
plasma L-Phe concentrations to ensure the efficacy of the diet.  Recent recommendations 
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by NIH specify that dietary restriction should be continued and monitored indefinitely 
(10).  Studies have shown that adults who have abandoned L-Phe-restricted diets tend to 
have reduced attention span and slow information processing abilities and motor reaction 
time (10).  Tetrahydrobiopterin monotherapy is used as an experimental dietary approach 
that has shown much promise in patients with certain mutations in PAH gene, who 
exhibit a mild to moderate PKU phenotype, the treatment has often resulted in a 
progressive relief or withdrawal from the Phe restricted diet of treated subjects (56-59).  
Another experimental approach for treatment of PKU is gene therapy, where an 
epidermal transduced skin patch is used to handle the excess L-Phe in blood plasma (60, 
61).  Phenylalanine ammonia lyase (PAL) treatment, where by L-Phe is enzymatically 
degraded to harmless metabolites such as ammonia and trans-cinnamic acid, the latter of 
which is excreted in urine as hippurate, is yet another alternative to lower L–Phe plasma 
levels in PKU patients, (62). 
The ECA developed in our laboratory is based on coupling the enzymatic 
oxidation of L-Phe to phenylpyruvate with a tetrazolium dye reduction to a formazan 
product via an electron mediator PMS and the cofactor NAD+.  As opposed to previous 
work on ECAs, our assay uses MTS that produces a water-soluble formazan product.  
Previous investigators have used INT or MTT, which upon oxidation yield formazan 
products not readily soluble in aqueous media (21, 22, 24, 27). 
A second advantage of our methodology is that much less sample preparation is 
required than in previously developed ECAs.  For example, DBS samples had to be 
eluted and / or deproteinized with H2O / alcohol or trichloroacetic acid (TCA) / perchloric 
acid (PCA) / SSA for an extensive period prior to measuring L-Phe level in the sample 
(22, 24, 25, 27, 28, 29, 31, 32).  Similarly, plasma samples were deproteinized prior to 
use in other ECAs (21, 23, 26, 30).  In the procedures described here, the sample 
preparation is limited to removal of blood cells via centrifugation, and material losses 
resulting from extensive analyte manipulation are therefore minimized.  In addition, for 
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DBS specimens, analyte recovery depends on blood hematocrit, blood spot size and 
preparation, duration of elution and elution conditions, filter paper type and the portion of 
filter paper used in analysis, thus further complicating the determination of L-Phe in 
comparison with the direct measurement of plasma L-Phe (50, 51).  Furthermore, 
quantitation of AAs from biological matrices without derivatization is advantageous 
because it eliminates the need for extra reagents and minimizes analysis errors introduced 
by derivative stability, side reactions, yield issues and reagent interference.  It should be 
noted that some of the previously developed ECAs required pre-equilibration of the L-
Phe-containing sample with the enzyme / cofactor mixture for approximately 30 minutes 
prior to addition of other ECA reagents as shown in Table 3 - 1.  The assay methodology 
described in this chapter does not require a pre-equilibration step prior to 
spectrophotometric measurement. 
Our ECA-measured L-Phe concentrations were compared with PAA-measured 
values obtained with the same but deproteinized plasma samples collected pre- and post-
‘PKU’ camp.  A Pearson correlation coefficient of 0.956 was obtained.  Similar Pearson 
correlation coefficients of 0.976 and 0.988, respectively, were obtained when L-Phe 
values measured by PAA were compared with those determined by HPLC and MS/MS 
analyses carried out on derivatized DBS eluates. 
The agreement between PAA and ECA or HPLC or MS/MS was further 
investigated using Bland and Altman plots.  PAA-measured L-Phe concentrations are on 
average 0.065 mM lower than ECA-measured values, which could be due to losses 
incurred during the deproteinization procedure.  PAA-measured L-Phe concentrations are 
on average 0.14 mM and 0.10 mM higher than values obtained by MS/MS and HPLC, 
respectively, which may be a result of analyte losses incurred during elution and 
derivatization of DBS eluates.  Fifty seven percent of the L-Phe measurements exhibit 
differences below 0.14 mM and 0.1 mM, respectively, when MS/MS and HPLC results 
were compared with PAA data in the 0 to 0.8 mM L-Phe concentration range.  A similar 
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trend was not observed when ECA results were compared with PAA measurements, 
which indicates a greater consistency of ECA in its ability to measure plasma L-Phe 
regardless of the concentration range.  It should be noted that the majority of measured L-
Phe differences lie within the d ± 2 × SD range of the bias plots. 
Considering the current consensus in the literature regarding the need for 
monitoring L-Phe concentration in plasma of PKU patients over their entire life spans, 
the necessity for a robust and efficient home-monitoring methodology is quite evident.  
The need for ongoing monitoring of plasma L-Phe levels is underscored by the 
measurements carried out in this study, which show the overall mean L-Phe 
concentration amongst participants at the beginning of “PKU camp” is 0.92 mM, which 
is higher than it should be.  At the end of camp the average L-Phe concentration was 
reduced by approximately 0.29 mM.  Hence PKU patients would derive a significant 
benefit from a methodology, which would enable them to measure plasma L-Phe levels at 
home.  Convenient monitoring on a day-to-day basis would provide a correlation of diet 
and body chemistry of PKU patients, which could increase the patient’s understanding of 
the condition and improves his or her motivation for effective dietary management of 
PKU. 
In summary, we report here ECA-determined L-Phe concentrations are indeed 
comparable to PAA-measured values for a broad range of plasma L-Phe levels, based on 
Pearson correlation coefficient of 0.951 and the Bland and Altman analysis.  Preliminary 
studies have also been carried to investigate the feasibility of making multi-layer films 
for L-Phe quantitation.  Thus far, the ECA reagents were shown to function in an 
immobilized format in a gelatin matrix and a linear response could be obtained for a 0 to 
10 mM L-Phe range.  The preparation and formulation of FRL and SL films still requires 
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